

# Lesotho

# **Country Operational Plan**

## FY 2017



## **Budget Summary Reports**

### Summary of Planned Funding by Agency and Funding Source

Agency	GAP	Funding Source GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
State		306,717		306,717	0	306,717
USAID		27,346,396	6,400,000	33,746,396	3,280,568	37,026,964
DOD		320,527		320,527	300,000	620,527
PC		400,000		400,000	317,000	717,000
HHS/CDC	512,500	26,784,342		27,296,842	1,753,355	29,050,197
State/AF		150,000		150,000	0	150,000
Total	512,500	55,307,982	6,400,000	62,220,482	5,650,923	67,871,405

### Summary of Planned Funding by Budget Code and Agency

	Agency					On Hold		
Budget Code	State	DOD	HHS/CDC	PC	State/AF	USAID	Amount	Total
CIRC		2,824				578,735	0	581,559
НВНС		28,672	1,404,786		60,000	1,520,820	0	3,014,278
нкір				213,683	30,000	4,785,176	0	5,028,859
HLAB		2,824	797,698				0	800,522
HTXS		177,493	11,688,663			11,244,346	0	23,110,502
HVAB						100,000	0	100,000
нуст		28,594	6,982,438			1,400,126	0	8,411,158
HVMS	306,717	30,255	618,581	121,641		1,915,987	0	2,993,181
HVOP		2,824	712,085	64,676		6,818,737	0	7,598,322
HVSI		2,824	1,338,131			330,716	0	1,671,671
НУТВ		43,984	2,268,598			2,945,894	0	5,258,476
мтст			165,126			333,642	0	498,768

Custom 2017-07-20 18:41 EDT FACTS Info v3.8.21.10



	306,717	320,527	27,296,842	400,000	150.000	33,746,396	0	62,220,482
PDTX		178	567,624			886,155	0	1,453,957
PDCS		55	482,582		60,000	211,267	0	753,904
OHSS			270,530			674,795	0	945,325



## **Technical Areas**

### **Technical Area Summary**

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	2,978,384	0
НКІД	4,848,869	0
НУТВ	5,061,215	0
PDCS	699,885	0
Total Technical Area Planned Funding:	13,588,353	0

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	660,000	0
HVSI	830,000	0
OHSS	689,873	0
Total Technical Area Planned	0.470.070	
Funding:	2,179,873	U

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	389,849	0
HVAB	100,000	0
НУСТ	8,353,242	0
HVOP	7,520,604	0
МТСТ	432,625	0
Total Technical Area Planned Funding:	16,796,320	0

Approved



#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	22,906,249	0
PDTX	1,399,938	0
Total Technical Area Planned	24 200 407	
Funding:	24,306,187	U



## **Technical Area Summary Indicators and Targets**

Indicator Number	Label	2018
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,619
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
	By Age (Denominator): <15-19	9,313
	By Age (Denominator): 20-24	16,224
	By Age (Denominator): 25-49	20,990
	By Age (Denominator): 50+	0
	By Number of known positives: Unknown Age	
	By Number of known positives: <10	0
	By Number of known positives: 10- 14	0
	By Number of known positives: 15- 19	1,591
	By Number of known positives: 20- 24	2,794
	By Number of known positives: 25-	3,587



	49	
	By Number of known positives: 50+	0
	By Number of new positives:	
	Unknown Age	0
	By Number of new positives: <10	0
	By Number of new positives: 10-14	0
	By Number of new positives: 15-19	767
	By Number of new positives: 20-24	1,345
	By Number of new positives: 25-49	1,715
	By Number of new positives: 50+	0
	By Number of new negative: Unknown Age	0
	By Number of new negative: <10	0
	By Number of new negative: 10-14	0
	By Number of new negative: 15-19	6,757
	By Number of new negative: 20-24	
	By Number of new negative: 25-49	15,145
	By Number of new negative: 50+	0
	By Age (Numerator): Unknown Age	
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	0
	By Age (Numerator): 15-19	9,114
	By Age (Numerator): 20-24	15,932
	By Age (Numerator): 25-49	20,573
	By Age (Numerator): 50+	0
	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of	25 %
PMTCT_ART_DSD	mother-to-child-transmission (MTCT) during pregnancy	
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-	11,237



	transmission (MTCT) during	
	pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,619
	New on ART	5,653
	Already on ART at beginning of current pregnancy	5,584
	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	50,183
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	11,478
	By Age: 15-19	13,440
	By Age: 20-24	13,534
	By Age: 25-29	11,463
	By Age: 30-49	172
VMMC_CIRC_DSD	By Age: 50+	96
	By HIV status: Number of HIV- positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV- negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	50,183



	By circumcision technique: Device- based VMMC	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up	
	care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	23,993
	Male 10-14	
PrEP_NEW_DSD	Male 15-19	788
	Male 20-24	765
	Male 25-49	2,573
	Male 50+	1,142
	Female 10-14	
	Female 15-19	2,799
	Female 20-24	2,790
	Female 25-49	9,329
	Female 50+	3,807
	(15-19)	
	(20-24)	



	FSW	570
	MSM	951
	TG	
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	85,830
	Total number of people in the target population	
	Age/sex: 10-14 Male	1,548
PP_PREV_DSD	Age/sex: 15-19 Male	3,573
	Age/sex: 20-24 Male	5,030
	Age/sex: 25-49 Male	19,524
	Age/sex: 50+ Male	1,696
	Age/sex: 10-14 Female	21,113
	Age/sex: 15-19 Female	12,289
	Age/sex: 20-24 Female	13,583
	Age/sex: 25-49 Female	6,236
	Age/sex: 50+ Female	1,237
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum	n/a



	components during the reporting period (TA-only)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,997
	Total number of people in the target population	
	Age/sex: 10-14 Male	394
	Age/sex: 15-19 Male	283
	Age/sex: 20-24 Male	150
	Age/sex: 25-49 Male	33
	Age/sex: 50+ Male	9
	Age/sex: 10-14 Female	479
	Age/sex: 15-19 Female	435
	Age/sex: 20-24 Female	138
	Age/sex: 25-49 Female	55
	Age/sex: 50+ Female	18
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV	
	preventive interventions that are based on evidence and/or meet the	n/a
KP_PREV_DSD	minimum standards required (DSD)	
	Number of key populations reached with individual and/or small group level HIV preventive interventions	6,599
	that are based on evidence and/or meet the minimum standards	



required	
Total estimated number of key population in the catchment area	
· · ·	
By key population type: Men who	
have sex with men who are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	4 4 9 4
individual and/or small group level	4,131
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	2,468
	_,



sex workers (FSW) (Numerator:
Number of key populations reached
with individual and/or small group
level HIV preventive interventions
that are based on evidence and/or
meet the minimum standards
required)
By key population type: Males who
inject drugs ( Male PWID)
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Females
who inject drugs (Female PWID)
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: People in
prisons and enclosed settings
(Numerator: Number of key
populations reached with individual
and/or small group level HIV
preventive interventions that are
based on evidence and/or meet the
minimum standards required)
By key population type: Female
sex workers (FSW) (Denominator:
Total estimated number of key
population in the catchment area)
By key population type: People in



prisons and enclosed settings
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type: Men who
have sex with men who are sex
workers (Denominator: Total
estimated number of key
population in the catchment area
By key population type: Men who
have sex with men who are NOT
sex workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type:
Transgender who are sex workers
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type:
Transgender who are NOT sex
workers (Denominator: Total
estimated number of key
population in the catchment area)
By key population type: Males who
inject drugs ( Male PWID)
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type: Females
who inject drugs (Female PWID)
(Denominator: Total estimated
number of key population in the
catchment area)
By key population type: Men who
have sex with men/Transgender
nave sex with men/ nansyenuel



	(MSM/TG) (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By key population type: MSM/TG	
	who are male sex workers (subset	
	MSM/TG) (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	TB_STAT_DSD Percentage of	
	registered new and relapsed TB	
	cases with documented HIV status.	100 %
	Number of registered new and	
	relapsed TB cases with	15,576
TB_STAT_DSD	documented HIV status, during the	
	reporting period.	
	Total number of registered new and	15 000
	relapsed TB cases, during the	15,626
	reporting period.	
	Age/Sex: <1 (Numerator: Number	
	of registered new and relapsed TB	
	cases with documented HIV status,	
	during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number	



of registered new and relapsed TB	
cases with documented HIV status,	
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	



documented HIV status, during the reporting period) Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 9,390 documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 193		
Age/Sex: Female 20-24         (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 25-49         (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Agergated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       9,390         Aggregated Age/Sex: Smale 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       9,390         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       193         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       193         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       193	•	
Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 25-49         (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Agergated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)		
new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       264         Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       9,390         Aggregated Age/Sex: Status, during the reporting period)       9,390         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       193         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       193         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       193         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       5,729	5	
documented HIV status, during the reporting period) Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with gocumented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with		
reporting period) Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 193		
Age/Sex: Female 25-49         (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)         Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with       193	_	
(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases withAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	reporting period)	
new and relapsed TB cases with documented HIV status, during the reporting period)Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729	Age/Sex: Female 25-49	
documented HIV status, during the reporting period)Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729	(Numerator: Number of registered	
reporting period)Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with 9,390 documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases withAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	new and relapsed TB cases with	
Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729	documented HIV status, during the	
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729	reporting period)	
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729	Age/Sex: Female 50+ (Numerator:	
relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with fully status, during the reporting period)		
documented HIV status, during the reporting period)Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729	•	
reporting period) Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with 264 documented HIV status, during the reporting period) Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with 9,390 documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 5,729		
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729	_	
(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 40cumented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729		
new and relapsed TB cases with documented HIV status, during the reporting period)264Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729		
documented HIV status, during the reporting period)documented HIV status, during the reporting period)Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 193193documented HIV status, during the reporting period)193Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with 40cumented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729		264
reporting period)Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729		204
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729	-	
Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)5,729		
new and relapsed TB cases with documented HIV status, during the reporting period)9,390Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with and relapsed TB cases with5,729		
documented HIV status, during the reporting period)documented HIV status, during the reporting period)Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729		0.000
reporting period) Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 5,729		9,390
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729	-	
(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)193Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with5,729		
new and relapsed TB cases with 193 documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 5,729		
documented HIV status, during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 5,729	(Numerator: Number of registered	
reporting period) Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 5,729	new and relapsed TB cases with	193
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with 5,729	documented HIV status, during the	
(Numerator: Number of registered new and relapsed TB cases with 5,729	reporting period)	
new and relapsed TB cases with 5,729	Aggregated Age/Sex: Female 15+	
new and relapsed TB cases with	(Numerator: Number of registered	E 700
documented HIV status, during the	new and relapsed TB cases with	5,729
	documented HIV status, during the	



reporting pariod)
reporting period)
Result: Known HIV positive at
service entry
Result: New HIV positive
Result: HIV Negative
Age/Sex: <1 (Denominator: Total
number of registered new and
relapsed TB cases, during the
reporting period.)
Age/Sex: 1-9 (Denominator: Total
number of registered new and
relapsed TB cases, during the
reporting period.)
Age/Sex: Male 10-14
(Denominator: Total number of
registered new and relapsed TB
cases, during the reporting period.)
Age/Sex: Male 15-19
(Denominator: Total number of
registered new and relapsed TB
cases, during the reporting period.)
Age/Sex: Male 20-24
(Denominator: Total number of
registered new and relapsed TB
cases, during the reporting period.)
Age/Sex: Male 25-49
(Denominator: Total number of
registered new and relapsed TB
cases, during the reporting period.)
Age/Sex: Male 50+ (Denominator:
Total number of registered new and
relapsed TB cases, during the
reporting period.)
Age/Sex: Female 10-14
(Denominator: Total number of



HTC_TST_DSD	Number of individuals who received	1,138,157
	cases, during the reporting period)	
	registered new and relapsed TB	5,741
	(Denominator: Total number of	
	Aggregated Age/Sex: Female 15+	
	cases, during the reporting period)	
	registered new and relapsed TB	193
	(Denominator: Total number of	
	Aggregated Age/Sex: Female <15	
	cases, during the reporting period)	
	(Denominator: Total number of registered new and relapsed TB	9,428
	Aggregated Age/Sex: Male 15+	
	cases, during the reporting period)	
	registered new and relapsed TB	
	(Denominator: Total number of	264
	Aggregated Age/Sex: Male <15	
	cases, during the reporting period.)	
	registered new and relapsed TB	
	(Denominator: Total number of	
	Age/Sex: Female 50+	
	cases, during the reporting period.)	
	registered new and relapsed TB	
	(Denominator: Total number of	
	Age/Sex: Female 25-49	
	cases, during the reporting period.)	
	` registered new and relapsed TB	
	(Denominator: Total number of	
	Age/Sex: Female 20-24	
	cases, during the reporting period.)	
	registered new and relapsed TB	
	(Denominator: Total number of	
	Age/Sex: Female 15-19	
	cases, during the reporting period.)	
	registered new and relapsed TB	



T&C services for HIV and received	
their test results during the past 12	
months	
By Test Result: Positive	97,279
ervice Delivery Point (Community)	
omebased testing: 10-14,	
emale, Negative	
ervice Delivery Point (Community)	
omebased testing: 10-14,	0
emale, Positive	
Service Delivery Point (Community)	
Homebased testing: 10-14, Male,	
legative	
Service Delivery Point (Community)	
lomebased testing: 10-14, Male,	0
Positive	
Service Delivery Point (Community)	
lomebased testing: 15-19,	
Female, Negative	
Service Delivery Point (Community)	
Homebased testing: 15-19,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: 15-19, Male,	
Negative	
Service Delivery Point (Community)	
Homebased testing: 15-19, Male,	
Positive	
Service Delivery Point (Community)	
Homebased testing: 20-24,	
Female, Negative	
Service Delivery Point (Community)	
lomebased testing: 20-24,	
emale, Positive	
Service Delivery Point (Community)	



Homebased testing: 20-24, Male, Negative	
Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	0
Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	0



Service Delivery Point (Community) Homebased testing: Unknown Age,	0
Male, Negative Service Delivery Point (Community) Homebased testing: Unknown Age,	0
Male, Positive	
Service Delivery Point (Community) Homebased testing: <1, Negative	0
Service Delivery Point (Community) Homebased testing: <1, Positive	0
Service Delivery Point (Community) Homebased testing: 1-9, Negative	
Service Delivery Point (Community) Homebased testing: 1-9, Positive	0
Service Delivery Point by Agg Age (Community) Homebased testing:	
<15, Female, Negative	
Service Delivery Point by Agg Age	
(Community) Homebased testing: <15, Female, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
<pre>&lt;15, Male, Negative</pre>	
Service Delivery Point by Agg Age	
(Community) Homebased testing: <15, Male, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
15+, Female, Negative	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
15+, Female, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
15+, Male, Negative	



Service Delivery Point by Agg Age	
(Community) Homebased testing: 15+, Male, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Negative	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Positive	
Service Delivery Point by Agg Age	
(Community) Homebased testing:	
Unknown Age, Male, Negative	
Service Delivery Point by Agg Age	
(Community) by Aggregated Age:	
Homebased testing: Unknown Age,	
Male, Positive	
Service Delivery Point (Facility)	488
Inpatient: 10-14, Female, Negative	
Service Delivery Point (Facility)	3
Inpatient: 10-14, Female, Positive	<b>.</b>
Service Delivery Point (Facility)	525
Inpatient: 10-14, Male, Negative	
Service Delivery Point (Facility)	3
Inpatient: 10-14, Male, Positive	
Service Delivery Point (Facility)	373
Inpatient: 15-19, Female, Negative	
Service Delivery Point (Facility)	33
Inpatient: 15-19, Female, Positive	
Service Delivery Point (Facility)	219
Inpatient: 15-19, Male, Negative	
Service Delivery Point (Facility)	6
Inpatient: 15-19, Male, Positive	-
Service Delivery Point (Facility)	1,166
 Inpatient: 20-24, Female, Negative	.,



Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	108
Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	551
Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	55
Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	7,961
Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	793
Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	5,274
Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	523
Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,082
Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	212
Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,284
Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	128
Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	



Service Delivery Point (Facility) Inpatient: <1, Negative	185
Service Delivery Point (Facility) Inpatient: <1, Positive	0
Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,662
Service Delivery Point (Facility) Inpatient: 1-9, Positive	14
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	



L	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	0
Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	0
Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	0
Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	0
Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,768
Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	294
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	2,238
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	175
Service Delivery Point (Community) Mobile Testing: 20-24, Female,	11,183



Negative	
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	892
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	5,879
ervice Delivery Point (Community) Iobile Testing: 20-24, Male, Positive	482
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	83,931
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	6,673
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	56,184
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	4,485
Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	20,887
Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1,670
ervice Delivery Point (Community) lobile Testing: 50+, Male, legative	12,542
Service Delivery Point (Community) Nobile Testing: 50+, Male, Positive	997
ervice Delivery Point (Community) lobile Testing: Unknown Age,	0



Female, Negative	
Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
Service Delivery Point (Community) Mobile Testing: <1, Negative	0
Service Delivery Point (Community) Mobile Testing: <1, Positive	0
Service Delivery Point (Community) Mobile Testing: 1-9, Negative	0
Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	
Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	
Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	
Service Delivery Point by Agg Age(Community) Mobile Testing:	



15+, Female, Positive	
Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	
Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	
Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	16,671
Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	156
Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	18,264
Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	155
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	6,730
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	900



Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,929
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	537
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	21,882
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,664
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	9,924
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,362
Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	143,153
Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	19,913
Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	94,645
Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	12,983
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	38,147
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	5,390
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	23,758
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3,283
Service Delivery Point (Facility) Other PITC: Unknown Age,	



Female, Negative	
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
Service Delivery Point (Facility)Other PITC: <1, Negative	6,389
Service Delivery Point (Facility) Other PITC: <1, Positive	35
Service Delivery Point (Facility) Other PITC: 1-9, Negative	57,475
Service Delivery Point (Facility) Other PITC: 1-9, Positive	540
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female,	



Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	866
Service Delivery Point (Community) Other: 10-14, Female, Positive	4
Service Delivery Point (Community) Other: 10-14, Male, Negative	869
Service Delivery Point (Community) Other: 10-14, Male, Positive	3
Service Delivery Point (Community) Other: 15-19, Female, Negative	390
Service Delivery Point (Community) Other: 15-19, Female, Positive	4
Service Delivery Point (Community) Other: 15-19, Male, Negative	229



Service Delivery Point (Community) Other: 15-19, Male, Positive	1
Service Delivery Point (Community) Other: 20-24, Female, Negative	1,163
Service Delivery Point (Community) Other: 20-24, Female, Positive	22
Service Delivery Point (Community) Other: 20-24, Male, Negative	617
Service Delivery Point (Community) Other: 20-24, Male, Positive	7
Service Delivery Point (Community) Other: 25-49, Female, Negative	8,865
Service Delivery Point (Community) Other: 25-49, Female, Positive	191
Service Delivery Point (Community) Other: 25-49, Male, Negative	5,938
Service Delivery Point (Community) Other: 25-49, Male, Positive	132
Service Delivery Point (Community) Other: 50+, Female, Negative	2,185
Service Delivery Point (Community) Other: 50+, Female, Positive	54
Service Delivery Point (Community) Other: 50+, Male, Negative	1,300
Service Delivery Point (Community) Other: 50+, Male, Positive	26
Service Delivery Point (Community) Other: Unknown Age, Female, Negative	0
Service Delivery Point (Community) Other: Unknown Age, Female, Positive	0
Service Delivery Point (Community) Other: Unknown Age, Male,	0



Negative	
Service Delivery Point (Community) Other: Unknown Age, Male, Positive	0
Service Delivery Point (Community) Other: <1, Negative	0
Service Delivery Point (Community) Other: <1, Positive	0
Service Delivery Point (Community) Other: 1-9, Negative	3,120
Service Delivery Point (Community) Other: 1-9, Positive	25
Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	
Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: 15+, Male,	



Positive	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Pediatric : <5 Negative	10,910
Service Delivery Point (Facility) Pediatric : <5 Positive	352
Service Delivery Point (Facility) TB: 10-14, Female, Negative	380
Service Delivery Point (Facility) TB: 10-14, Female, Positive	2
Service Delivery Point (Facility) TB: 10-14, Male, Negative	437
Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
Service Delivery Point (Facility) TB: 15-19, Female, Negative	362
Service Delivery Point (Facility) TB: 15-19, Female, Positive	59
Service Delivery Point (Facility) TB: 15-19, Male, Negative	210
Service Delivery Point (Facility) TB: 15-19, Male, Positive	32
Service Delivery Point (Facility) TB:	1,166



	20-24, Female, Negative	
	Service Delivery Point (Facility) TB:	160
	20-24, Female, Positive	
	Service Delivery Point (Facility) TB:	529
	20-24, Male, Negative	
	Service Delivery Point (Facility) TB:	83
	20-24, Male, Positive	00
	Service Delivery Point (Facility) TB:	7,749
	25-49, Female, Negative	7,749
	Service Delivery Point (Facility) TB:	1,184
	25-49, Female, Positive	1,104
	Service Delivery Point (Facility) TB:	5,095
	25-49, Male, Negative	5,095
	Service Delivery Point (Facility) TB:	784
	25-49, Male, Positive	704
	Service Delivery Point (Facility) TB:	2,060
	50+, Female, Negative	2,000
	Service Delivery Point (Facility) TB:	324
	50+, Female, Positive	
	Service Delivery Point (Facility) TB:	1,281
	50+, Male, Negative	
	Service Delivery Point (Facility) TB:	199
	50+, Male, Positive	
	Service Delivery Point (Facility) TB:	
	Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB:	
	Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB:	
	Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB:	
	Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB:	151
	<1, Negative	101
	Service Delivery Point (Facility) TB:	0



<1, Positive	
Service Delivery Point (Facility) TB: 1-9, Negative	1,356
Service Delivery Point (Facility) TB: 1-9, Positive	11
Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	
Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	
Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	
Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male,	



Positive		
	Delivery Point (Facility) <1, Negative	0
	Delivery Point (Facility) <1, Positive	0
	Delivery Point (Facility) 10-14, Negative	0
	Delivery Point (Facility) 10-14, Positive	0
	Delivery Point (Facility) 15-19, Negative	12,406
	Delivery Point (Facility) 15-19, Positive	186
	Delivery Point (Facility) 1-9, Negative	0
	Delivery Point (Facility) 1-9, Positive	0
	Delivery Point (Facility) 20-24, Negative	4,030
	Delivery Point (Facility) 20-24, Positive	125
	Delivery Point (Facility) 25-49, Negative	2,424
	Delivery Point (Facility) 25-49, Positive	716
	Delivery Point (Facility) 50+, Negative	94
	Delivery Point (Facility) 50+, Positive	1
	Delivery Point (Facility) Unknown Age, Negative	0
	Delivery Point (Facility) Unknown Age, Positive	0
Service I	Delivery Point (Facility)	



VMMC: <15, Negative	
Service Delivery Point by Agg Age	
(Facility) VMMC: <15, Positive	
Service Delivery Point by Agg Age	
(Facility) VMMC: 15+, Negative	
Service Delivery Point by Agg Age	
(Facility) VMMC: 15+, Positive	
Service Delivery Point by Agg Age	
(Facility) VMMC: Unknown Age,	
Negative	
Service Delivery Point by Agg Age	
(Facility) VMMC: Unknown Age,	
Positive	
Service Delivery Point (Facility)	3,980
Index: 10-14, Female, Negative	3,900
Service Delivery Point (Facility)	30
Index: 10-14, Female, Positive	
Service Delivery Point (Facility)	4,383
Index: 10-14, Male, Negative	4,000
Service Delivery Point (Facility)	29
Index: 10-14, Male, Positive	25
Service Delivery Point (Facility)	1,863
Index: 15-19, Female, Negative	1,000
Service Delivery Point (Facility)	195
Index: 15-19, Female, Positive	100
Service Delivery Point (Facility)	1,090
Index: 15-19, Male, Negative	1,000
Service Delivery Point (Facility)	107
Index: 15-19, Male, Positive	101
Service Delivery Point (Facility)	6,127
Index: 20-24, Female, Negative	5,121
Service Delivery Point (Facility)	568
Index: 20-24, Female, Positive	
Service Delivery Point (Facility)	2,658



ty)	297
ty) ive	38,911
ty) /e	4,362
ty)	25,487
ty)	2,822
ty) Ə	10,578
ty)	1,210
ty)	6,677
ty)	721
ty) ə,	
ty) ə,	
ty)	
ty)	
ty)	1,522
ty)	3



Index. 1 Desitive	
Index: <1, Positive	
Service Delivery Point (Facility)	13,788
Index: 1-9, Negative	
Service Delivery Point (Facility)	113
Index: 1-9, Positive	
Service Delivery Point Agg Age	
(Facility) Index: <15, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: <15, Female,	
Positive	
Service Delivery Point Agg Age	
(Facility) Index: <15, Male,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: <15, Male, Positive	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Female,	
Positive	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Male,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Male, Positive	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
Female, Negative	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
Female, Positive	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
(. searcy) mask enknown rigo,	



Male, Negative	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
Male, Positive	
By Key Population: FSW, Negative	
By Key Population: FSW, Positive	
By Key Population: MSM, Negative	
By Key Population: MSM, Positive	
By Key Population: People in	
prisons and other enclosed	
settings, Negative	
By Key Population: People in	
prisons and other enclosed	
settings, Positive	
By Key Population: PWID,	
Negative	
By Key Population: PWID, Positive	
By Key Population: TG, Negative	
By Key Population: TG, Positive	
Service Delivery Point (Facility)	
Malnutrition: Negative	
Service Delivery Point (Facility)	
Malnutrition: Positive	
Service Delivery Point (Community)	
Index Mod: 10-14, Female,	1,733
Negative	
Service Delivery Point (Community)	14
Index Mod: 10-14, Female, Positive	14
Service Delivery Point (Community)	1,740
Index Mod: 10-14, Male, Negative	1,740
Service Delivery Point (Community)	12
Index Mod: 10-14, Male, Positive	12
Service Delivery Point (Community)	1,622
Index Mod: 15-19, Female,	1,022



Negative	
Service Delivery Point (Community)	
Index Mod: 15-19, Female, Positive	179
Service Delivery Point (Community)	
Index Mod: 15-19, Male, Negative	956
Service Delivery Point (Community)	100
Index Mod: 15-19, Male, Positive	106
Service Delivery Point (Community)	
Index Mod: 20-24, Female,	4,828
Negative	
Service Delivery Point (Community)	538
Index Mod: 20-24, Female, Positive	550
Service Delivery Point (Community)	2,535
Index Mod: 20-24, Male, Negative	2,000
Service Delivery Point (Community)	283
Index Mod: 20-24, Male, Positive	200
Service Delivery Point (Community)	
Index Mod: 25-49, Female,	36,803
Negative	
Service Delivery Point (Community)	4,093
Index Mod: 25-49, Female, Positive	.,
Service Delivery Point (Community)	24,664
Index Mod: 25-49, Male, Negative	,
Service Delivery Point (Community)	2,742
Index Mod: 25-49, Male, Positive	_,
Service Delivery Point (Community)	9,067
Index Mod: 50+, Female, Negative	-,
Service Delivery Point (Community)	1,009
Index Mod: 50+, Female, Positive	-,
Service Delivery Point (Community)	5,391
Index Mod: 50+, Male, Negative	- ,
Service Delivery Point (Community)	603
Index Mod: 50+, Male, Positive	
Service Delivery Point (Community)	0



Index Mod: Unknown Age, Female, Negative	
Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
Service Delivery Point (Community) Index Mod: <1, Negative	0
Service Delivery Point (Community) Index Mod: <1, Positive	0
Service Delivery Point (Community) Index Mod: 1-9, Negative	6,242
Service Delivery Point (Community) Index Mod: 1-9, Positive	67
Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	
Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	
Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	
Service Delivery Point by Agg Age	



(Community) Index Mod: 15+, Female, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	
Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
Service Delivery Point (Facility) ANC: <1, Negative	0
Service Delivery Point (Facility) ANC: <1, Positive	0
Service Delivery Point (Facility) ANC: 10-14, Negative	0
Service Delivery Point (Facility) ANC: 10-14, Positive	0
Service Delivery Point (Facility) ANC: 15-19, Negative	3,100
Service Delivery Point (Facility) ANC: 15-19, Positive	268
Service Delivery Point (Facility) ANC: 1-9, Negative	0



Service Delivery Point (Facility) ANC: 1-9, Positive	0
Service Delivery Point (Facility) ANC: 20-24, Negative	8,186
Service Delivery Point (Facility) ANC: 20-24, Positive	713
Service Delivery Point (Facility) ANC: 25-49, Negative	16,924
Service Delivery Point (Facility) ANC: 25-49, Positive	1,476
Service Delivery Point (Facility) ANC: 50+, Negative	54
Service Delivery Point (Facility) ANC: 50+, Positive	0
Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	
Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	
Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	
Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	
Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	
Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	



Service Delivery Point (Facility)	
VCT: 10-14, Female, Positive	
Service Delivery Point (Facility)	
VCT: 10-14, Male, Negative	
Service Delivery Point (Facility)	
VCT: 10-14, Male, Positive	
Service Delivery Point (Facility)	10
VCT: 15-19, Female, Negative	42
Service Delivery Point (Facility)	
VCT: 15-19, Female, Positive	2
Service Delivery Point (Facility)	
VCT: 15-19, Male, Negative	37
Service Delivery Point (Facility)	
VCT: 15-19, Male, Positive	1
Service Delivery Point (Facility)	26
VCT: 20-24, Female, Negative	
Service Delivery Point (Facility)	2
VCT: 20-24, Female, Positive	
Service Delivery Point (Facility)	34
VCT: 20-24, Male, Negative	54
Service Delivery Point (Facility)	2
VCT: 20-24, Male, Positive	2
Service Delivery Point (Facility)	
VCT: 25-49, Female, Negative	95
Service Delivery Point (Facility)	
VCT: 25-49, Female, Positive	19
Service Delivery Point (Facility)	
VCT: 25-49, Male, Negative	85
Service Delivery Point (Facility)	13
VCT: 25-49, Male, Positive	
Service Delivery Point (Facility)	100
VCT: 50+, Female, Negative	
Service Delivery Point (Facility)	14
 VCT: 50+, Female, Positive	17



Service Delivery Point (Facility) VCT: 50+, Male, Negative	89
Service Delivery Point (Facility) VCT: 50+, Male, Positive	16
Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
Service Delivery Point (Facility) VCT:	
Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
Service Delivery Point (Facility) VCT: <1, Negative	
Service Delivery Point (Facility) VCT: <1, Positive	
Service Delivery Point (Facility) VCT: 1-9, Negative	
Service Delivery Point (Facility) VCT: 1-9, Positive	
Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	
Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	
Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	
Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	
Service Delivery Point by Agg Age (Facility) VCT: 15+, Female,	



Negative	
Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	
Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	
Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	0
Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	0
Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	0
Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	0
Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,210
Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	85
Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	718



Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	49
Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	3,609
Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	251
Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	1,896
Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	132
Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	27,537
Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	1,914
Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	18,494
Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	1,280
Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	6,783
Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	472
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	4,031
Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	281
Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	0
Service Delivery Point (Community) VCT Mod: Unknown Age, Male,	0



Negative	
Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	0
Service Delivery Point (Community) VCT Mod: <1, Negative	0
Service Delivery Point (Community) VCT Mod: <1, Positive	0
Service Delivery Point (Community) VCT Mod: 1-9, Negative	0
Service Delivery Point (Community) VCT Mod: 1-9, Positive	0
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	
Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male,	



	Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
	Number of people receiving post- GBV care	2,750
	By type of service: Physical and/or Emotional Violence (Other Post- GBV Care)	278
	By type of service: Sexual Violence (Post-Rape Care)	2,469
	By PEP service provision (related to sexual violence services provided)	2,234
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	
	<10, Female, Sexual Violence (Post-Rape Care)	
	<10, Male, Physical and/or Emotional Violence	
	<10, Male, Sexual Violence (Post- Rape Care)	
	10-14, Female, Physical and/or Emotional Violence	25
	10-14, Female, Sexual Violence	222



	(Post-Rape Care)	
	10-14, Male, Physical and/or	
	Emotional Violence	
	10-14, Male, Sexual Violence (Post-Rape Care)	25
	15-19, Female, Physical and/or Emotional Violence	98
	15-19, Female, Sexual Violence (Post-Rape Care)	893
	15-19, Male, Physical and/or Emotional Violence	20
	15-19, Male, Sexual Violence (Post-Rape Care)	97
	20-24, Female, Physical and/or Emotional Violence	97
	20-24, Female, Sexual Violence (Post-Rape Care)	881
	20-24, Male, Physical and/or Emotional Violence	13
	20-24, Male, Sexual Violence (Post-Rape Care)	97
	25-49, Female, Physical and/or Emotional Violence	19
	25-49, Female, Sexual Violence (Post-Rape Care)	173
	25-49, Male, Physical and/or Emotional Violence	
	25-49, Male, Sexual Violence (Post-Rape Care)	22
	50+, Female, Physical and/or Emotional Violence	2
	50+, Female, Sexual Violence (Post-Rape Care)	43
	50+, Male, Physical and/or	



	Emotional Violence	
	50+, Male, Sexual Violence (Post- Rape Care)	1
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	88,712
	Age/Sex: 10-14 Male	4,763
	Age/Sex: 15-17 Male	5,839
	By: Age/sex: Male 18-24	4,412
	By: Age/sex: Male 25+	4,987
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	11,241
	Age/Sex: 15-17 Female	21,810
OVC_SERV_DSD	By: Age/sex: 18-24 Female	10,372
	By: Age/sex: 25+ Female	10,880
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	43,653
	Required only for DREAMS	
	countries - By service, age and	
	sex: Education Support Female <1	
	Required only for DREAMS	
	countries - By service, age and sex: Education Support Female 10- 14	1,391
	Required only for DREAMS	895



countries - By service, age and sex: Education Support Female 17	
Required only for DREAMS countries - By service, age and sex: Education Support Female 24	259
Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	10
Required only for DREAMS countries - By service, age and sex: Education Support Male <	
Required only for DREAMS countries - By service, age and sex: Education Support Male 10	
Required only for DREAMS countries - By service, age and sex: Education Support Male 15	
Required only for DREAMS countries - By service, age and sex: Education Support Male 18	
Required only for DREAMS countries - By service, age and sex: Education Support Male 25	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Progr Female <1	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Progr Female 10-14	2.760
Required only for DREAMS	3,764



countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	833
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	5,746
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,497
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,030
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	432
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1,336
Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
Required only for DREAMS	6,908



countries - By service, age and	
sex: Social Protection Female 10-	
14	
Required only for DREAMS	
countries - By service, age and	11,091
sex: Social Protection Female 15-	11,001
17	
Required only for DREAMS	
countries - By service, age and	4 009
sex: Social Protection Female 18-	4,908
24	
Required only for DREAMS	
countries - By service, age and	530
sex: Social Protection Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male <1	
Required only for DREAMS	
countries - By service, age and	2,367
sex: Social Protection Male 10-14	
Required only for DREAMS	
countries - By service, age and	1,314
sex: Social Protection Male 15-17	
Required only for DREAMS	
countries - By service, age and	314
sex: Social Protection Male 18-24	
Required only for DREAMS	
countries - By service, age and	199
sex: Social Protection Male 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	
Female <1	
Required only for DREAMS	1,014
countries - By service, age and	1,014



•	
sex: Economic Strengthening Female 10-14	
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	4,165
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,358
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	8,497
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	35
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	102
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	457
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	2,043
Required only for DREAMS	



C	ountries - By service, age and	
S	ex: Other Services Female <1	
R	Required only for DREAMS	
C	ountries - By service, age and	1,819
s	ex: Other Services Female 10-14	
R	Required only for DREAMS	
C	ountries - By service, age and	1,278
S	ex: Other Services Female 15-17	
R	Required only for DREAMS	
С	ountries - By service, age and	550
s	ex: Other Services Female 18-24	
R	Required only for DREAMS	
C	ountries - By service, age and	3,847
s	ex: Other Services Female 25+	
R	Required only for DREAMS	
C	ountries - By service, age and	
s	ex: Other Services Male <1	
R	Required only for DREAMS	
С	ountries - By service, age and	1,684
30	ex: Other Services Male 10-14	
R	Required only for DREAMS	
С	ountries - By service, age and	1,355
S	ex: Other Services Male 15-17	
R	Required only for DREAMS	
С	ountries - By service, age and	401
s	ex: Other Services Male 18-24	
R	Required only for DREAMS	
С	ountries - By service, age and	993
56	ex: Other Services Male 25+	
A	.ge/Sex: <1	4,879
A	.ge/Sex: 1-9	9,530
R	Required only for DREAMS	
(	ountries - By service, age and	
S	ex: Education Support 1-9 Male	
R	Required only for DREAMS	



countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
Required only for DREAMS countries - By service, age and sex: Social Protection Programs	
Male 1-9 Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	
1-9 Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
Program Completion: Active Program Completion: Graduation	88,712
Program Completion: Transferred Program Completion: Exited without graduation	
By Aggregated Age/Sex: <18 Male By Aggregated Age/Sex: 18+ Male	
By Aggregated Age/Sex: <18 Female	
By Aggregated Age/Sex: 18+ Female	
Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	
Female 1-9 Required only for DREAMS countries - By service, age and	



	sex: Social Protection Programs	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Economic Strengthening	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Other Services Female 1-9	
	Number of active beneficiaries	
	served by PEPFAR OVC programs	1,258
	for children and families affected by	1,200
	HIV/AIDS	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	248
	Age/Sex: 15-17 Male	198
	By age/sex: 18-24 Male	88
OVC_SERV_TA	By age/sex: 25+ Male	6
	Age/Sex: 18+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	291
	Age/Sex: 15-17 Female	251
	By age/sex: 18-24 Female	84
	By age/sex: 25+ Female	11
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	988
	Required only for DREAMS	
	countries: By Service Area, age	
	and sex: Education Support	



Female <1	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Education Support	
Female 1-4	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Education Support	
Female 5-9	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Education Support	55
Female 10-14	
Required only for DREAMS	
countries: By Service Area, age	40
and sex: Education Support	46
Female 15-17	
Required only for DREAMS	
countries: By Service Area, age	0
and sex: Education Support	0
Female 18-24	
Required only for DREAMS	
countries: By Service Area, age	0
and sex: Education Support	0
Female 25+	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Education Support Male	
<1	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Education Support Male	
1-4	
Required only for DREAMS	
countries: By Service Area, age	



	1
and sex: Education Support Male 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	33
Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	13
Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	0
Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	0
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	0
Required only for DREAMS	111



countries: By Ser	-
and sex: Parentin Program Female	
Required only for countries: By Serv and sex: Parentin Program Female	DREAMS vice Area, age g/Caregiver
Required only for countries: By Serv and sex: Parentin Program Female	DREAMS vice Area, age g/Caregiver 0
Required only for countries: By Serv and sex: Parentin Program Male <1	vice Area, age ng/Caregiver
Required only for countries: By Ser and sex: Parentin Program Male 1-4	vice Area, age ng/Caregiver
Required only for countries: By Serv and sex: Parentin Program Male 5-9	vice Area, age ng/Caregiver
Required only for countries: By Serv and sex: Parentin Program Male 10	vice Area, age ng/Caregiver
Required only for countries: By Serv and sex: Parentin Program Male 15	vice Area, age 48 g/Caregiver 48
Required only for countries: By Serv and sex: Parentin Program Male 18	vice Area, age ng/Caregiver 0



	1
Required only for countries: By Ser and sex: Parentir Program Male 25	vice Area, age 282 g/Caregiver 282
Required only for countries: By Ser and sex: Social P <1	
Required only for countries: By Ser and sex: Social P 1-4	vice Area, age
Required only for countries: By Ser and sex: Social P 5-9	vice Area, age
Required only for countries: By Ser and sex: Social P 10-14	vice Area, age 34
Required only for countries: By Ser and sex: Social P 15-17	vice Area, age 27
Required only for countries: By Ser and sex: Social P 18-24	vice Area, age
Required only for countries: By Ser and sex: Social P 25+	vice Area, age
Required only for countries: By Ser and sex: Social P	



Required only for DREAMS countries: By Service Area, age	
and sex: Social Protection Male 1-4	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Social Protection Male 5-9	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Social Protection Male 10-	19
14	
Required only for DREAMS	
countries: By Service Area, age	16
and sex: Social Protection Male 15-	16
17	
Required only for DREAMS	
countries: By Service Area, age	2
and sex: Social Protection Male 18-	2
24	
Required only for DREAMS	
countries: By Service Area, age	86
and sex: Social Protection Male	00
25+	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Economic Strengthening	
Female <1	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Economic Strengthening	
Female 1-4	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Economic Strengthening	
Female 5-9	
Required only for DREAMS	0



countries: By Service Area, and sex: Economic Strength Female 10-14	•
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Female 15-17	age 111
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Female 18-24	age 38
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Female 25+	age 0
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Male <1	age
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Male 1-4	age
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Male 5-9	age
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Male 10-14	age 111
Required only for DREAMS countries: By Service Area, and sex: Economic Strength Male 15-17	age 38



	1
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	0
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	348
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	87
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	71
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	36
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas	0



Female 25+	
Age/Sex: <1	0
Age/Sex: 1-9	81
Required only for DREAMS	
countries: By Service Area, age	
and sex: Education Support 1-9	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	
Program 1-9	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Social Protection 1-9	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Economic Strengthening	
1-9	
Program Completion: Active	1,258
Program Completion: Graduated	
Program Completion: Transferred	
Program Completion: Exited	
without graduation	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Other Service Areas <1	
Required only for DREAMS	
countries: By Service Area, age	74
and sex: Other Service Areas Male	71
10-14	
Required only for DREAMS	
countries: By Service Area, age	26
	20
and sex: Other Service Areas Male	
and sex: Other Service Areas Male 15-17	



	countries: By Service Area, age	
	and sex: Other Service Areas Male	
	18-24	
	Required only for DREAMS	
	countries: By Service Area, age	217
	and sex: Other Service Areas Male	217
	25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18	
	Female	
	By Aggregated Age/Sex: 18+	
	Female	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Education Support 1-9 Female	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Parenting/Caregiver Program	
	1-9 Female	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Economic Strengthening 1-9	
	Female	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Other Service Areas 1-9	
	Female	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Social Protection 1-9 Female	
	Required only for DREAMS	
	countries: By Service Area, age	
	and sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-	100 %



positive new and relapsed	
registered TB cases on ART during	
TB treatment	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	10,964
ART during TB treatment during	
the reporting period	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	10,964
treatment during the reporting	,
period	
Age/Sex: <1 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: 1-9 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	



	the reporting period)
	Age/Sex: Male 20-24 (Numerator:
	The number of registered new and
	relapse TB cases with documented
	HIV-positive status who are on
	ART during TB treatment during
	the reporting period)
	Age/Sex: Male 25-49 (Numerator:
	The number of registered new and
	relapse TB cases with documented
	HIV-positive status who are on
	ART during TB treatment during
	the reporting period)
	Age/Sex: Male 50+ (Numerator:
	The number of registered new and
	relapse TB cases with documented
	HIV-positive status who are on
	ART during TB treatment during
	the reporting period)
	Age/Sex: Female 10-14
	(Numerator: The number of
	registered new and relapse TB
	cases with documented HIV-
	positive status who are on ART
	during TB treatment during the
	reporting period)
	Age/Sex: Female 15-19
	(Numerator: The number of
	registered new and relapse TB
	cases with documented HIV-
	positive status who are on ART
	during TB treatment during the
	reporting period)
	Age/Sex: Female 20-24
	(Numerator: The number of
	registered new and relapse TB
1	



cases with documented HIV-	
positive status who are on ART	
during TB treatment during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented HIV-	
positive status who are on ART	
during TB treatment during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented HIV-	185
positive status who are on ART	
during TB treatment during the	
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented HIV-	6,616
positive status who are on ART	
during TB treatment during the	
reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	134
cases with documented HIV-	
positive status who are on ART	



during TB treatment during the reporting period) Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV- positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: 51 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)		
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV- positive status who are on ART during TB treatment during the reporting period)       4,029         On ART: Bready on ART       0         On ART: Already on ART       1         On ART: New on ART       1         Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)       1         Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)       1         Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)       1         Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)       1         Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment       1         Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment       1	•	
(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)       4,029         On ART: Already on ART       On ART: Already on ART       Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)       Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14       (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14       (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 15-19       (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 15-19       (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 15-19       (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	reporting period)	
registered new and relapse TB cases with documented HIV- positive status who are on ART during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: 21 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	Aggregated Age/Sex: Female 15+	
cases with documented HIV-       4,029         positive status who are on ART       during TB treatment during the         reporting period)       On ART: Already on ART         On ART: New on ART       Age/Sex: >1 (Denominator: The         number of registered new and       relapse TB cases with documented         HIV-positive status during TB       treatment during the reporting         period)       Age/Sex: 1-9 (Denominator: The         Age/Sex: 1-9 (Denominator: The       number of registered new and         relapse TB cases with documented       HIV-positive status during TB         treatment during the reporting       period)         Age/Sex: 1-9 (Denominator: The       number of registered new and         relapse TB cases with documented       HIV-positive status during TB         treatment during the reporting       period)         Age/Sex: Male 10-14       (Denominator: The number of         registered new and relapse TB       cases with documented HIV-         positive status during TB treatment       during the reporting period)         Age/Sex: Male 15-19       (Denominator: The number of         registered new and relapse TB       cases with documented HIV-         positive status during TB treatment       during the reporting period)         Age/Sex: Male 15-19       (Denominator: The number of     <	(Numerator: The number of	
positive status who are on ART         during TB treatment during the         reporting period)         On ART: Already on ART         On ART: New on ART         Age/Sex: >1 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: Male 10-14         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive st	registered new and relapse TB	
during TB treatment during the reporting period) On ART: Already on ART On ART: New on ART Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting TB treatment during TB treatment during the reporting TB cases with documented HIV- positive status during TB treatment during the reporting TB treatment	cases with documented HIV-	4,029
reporting period) On ART: Already on ART On ART: New on ART Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	positive status who are on ART	
On ART: Already on ART         On ART: New on ART         Age/Sex: >1 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: Male 10-14         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         uring the reporting period)	during TB treatment during the	
On ART: New on ART         Age/Sex: >1 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: Male 10-14         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment	reporting period)	
Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	On ART: Already on ART	
number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	On ART: New on ART	
relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	Age/Sex: >1 (Denominator: The	
HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: 1-9 (Denominator: The         number of registered new and         relapse TB cases with documented         HIV-positive status during TB         treatment during the reporting         period)         Age/Sex: Male 10-14         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment	number of registered new and	
treatment during the reporting period) Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	relapse TB cases with documented	
period)Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	HIV-positive status during TB	
Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 10-14         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	treatment during the reporting	
number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	period)	
relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	Age/Sex: 1-9 (Denominator: The	
HIV-positive status during TB treatment during the reporting period)Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period)	number of registered new and	
treatment during the reporting period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	relapse TB cases with documented	
period) Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	HIV-positive status during TB	
Age/Sex: Male 10-14         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)         Age/Sex: Male 15-19         (Denominator: The number of         registered new and relapse TB         cases with documented HIV-         positive status during TB treatment         during the reporting period)	treatment during the reporting	
(Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	period)	
registered new and relapse TB cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	Age/Sex: Male 10-14	
cases with documented HIV- positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	(Denominator: The number of	
positive status during TB treatment during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	registered new and relapse TB	
during the reporting period) Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	cases with documented HIV-	
Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	positive status during TB treatment	
(Denominator: The number of registered new and relapse TB cases with documented HIV- positive status during TB treatment	during the reporting period)	
registered new and relapse TB cases with documented HIV- positive status during TB treatment	Age/Sex: Male 15-19	
cases with documented HIV- positive status during TB treatment	(Denominator: The number of	
positive status during TB treatment	registered new and relapse TB	
·	cases with documented HIV-	
during the reporting period)	positive status during TB treatment	
	during the reporting period)	



Age/Sex: Male 20-24
(Denominator: The number of
registered new and relapse TB
cases with documented HIV-
positive status during TB treatment
during the reporting period)
Age/Sex: Male 25-49
(Denominator: The number of
registered new and relapse TB
cases with documented HIV-
positive status during TB treatment
during the reporting period)
Age/Sex: Male 50+ (Denominator:
The number of registered new and
relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 10-14
(Denominator: The number of
registered new and relapse TB
cases with documented HIV-
positive status during TB treatment
during the reporting period)
Age/Sex: Female 15-19
(Denominator: The number of
registered new and relapse TB
cases with documented HIV-
positive status during TB treatment
during the reporting period)
Age/Sex: Female 20-24
(Denominator: The number of
registered new and relapse TB
`
registered new and relapse TB
registered new and relapse TB cases with documented HIV-



Age/Sex: Female 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented HIV-	
positive status during TB treatment	
during the reporting period)	
Age/Sex: Female 50+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented HIV-	
positive status during TB treatment	
during the reporting period)	
Aggregated Age/Sex: Male <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented HIV-	185
positive status during TB treatment	
during the reporting period)	
Aggregated Age/Sex: Male 15+	
(Denominator: The number of	
registered new and relapse TB	
cases with documented HIV-	6,616
positive status during TB treatment	
during the reporting period)	
Aggregated Age/Sex: Female <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented HIV-	134
positive status during TB treatment	
during the reporting period)	
Aggregated Age/Sex: Female 15+ (Denominator: The number of	
,	
registered new and relapse TB cases with documented HIV-	4,029
positive status during TB treatment	
during the reporting period)	



	TB_PREV_DSD TB_PREV_DSD	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	73,682
	period The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	81,678
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	662
	By Age/Sex (Denominator): <15, Male	676
	By Age/Sex (Denominator): 15+, Female	49,065
	By Age/Sex (Denominator): 15+, Male	31,275
	By Therapy type (Denominator): 6- 12 Month IPT	81,656
	By Therapy type (Denominator): Alternative Regimen	
	By Therapy type (Denominator): Continuous IPT	28
	By Age/Sex (Numerator): <15, Female	648
	By Age/Sex (Numerator): <15, Male	663



	By Age/Sex (Numerator): 15+, Female	44,169
	By Age/Sex (Numerator): 15+, Male	28,202
	By Therapy type (Numerator): 6-12 Month IPT	73,638
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	44
	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	1 %
	Number of ART patients who were started on TB treatment during the reporting period.	3,421
	Number of ART patients who were screened for TB at least once during the reporting period	244,576
	Numerator: By Aggregated Age/Sex: <15, Female	49
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	49
	Numerator: By Aggregated Age/Sex: 15+, Female	2,002
	Numerator: By Aggregated Age/Sex: 15+, Male	1,321
	Denominator: By Aggregated Age/Sex: <15, Female	4,871
	Denominator: By Aggregated Age/Sex: <15, Male	4,883
	Denominator: By Aggregated Age/Sex:15+, Female	143,248
	Denominator: By Aggregated	91,574



	Age/Sex:15+, Male	
	Denominator: By Screen Result: Negative	232,244
	Denominator: By Screen Result: Positive	12,332
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	12,322
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	184
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	12,138
	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,195
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	



	Sum of Infont Ago disaggragates	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive	56
	virological test result within 2 months of birth	50
	Number of infants with a positive	
	virological test result within 12	
	months of birth	
	Unknown, <= 2 months	0
	Unknown, 2 - 12 months	0
	Number of infants with a negative	
	virological test result within 2	8,977
	months of birth	
	Number of infants with a positive	
	virological test result between 2	65
	and 12 months of birth	
	Number of infants with a negative	
	virological test result between 2	2,097
	and 12 months of birth	
	Number of adults and children	
	receiving antiretroviral therapy	256,694
	(ART)	
	Age/Sex: 15-19 Male	2,758
TX_CURR_DSD	Age/Sex: 15-19 Female	4,633
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex <15	



	Sum of Aggregated Age/Sex 15+	
	Sum of Aggregated Age/Sex	
	disaggregates	
	Age/Sex: <1	635
	Age/Sex: <1-9	5,719
	Age/Sex: 10-14 Male	1,730
	Age/Sex: 10-14 Female	1,716
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	7,615
	Age/Sex: 25-49 Male	69,228
	Age/Sex: 50+ Male	16,772
	Age/Sex: 20-24 Female	13,981
	Age/Sex: 25-49 Female	104,496
	Age/Sex: 50+ Female	27,408
	Number of adults and children newly enrolled on antiretroviral	90,646
	therapy (ART)	74
	By Age/Sex: <1	74
	By Age/Sex: 1-9	779 243
TX_NEW_DSD	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	1,004
	By Age/Sex: 20-24 Male By Age/Sex: 25-49 Male	2,597 24,983
	By Age/Sex: 50+ Male	6,094
	By Age/Sex: 10-14 Female	234
	By Age/Sex: 15-19 Female	1,696
	By Age/Sex: 20-24 Female	5,031
	By Age/Sex: 25-49 Female	37,940
	By Age/Sex: 50+ Female	9,972
	Aggregated Grouping by Age: <1	3,312
	Aggregated Grouping by Age: <1 Aggregated Grouping by Age: <1 Male	



	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Pregnancy status	5,645
	Breastfeeding status	2
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	90 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records	195,430



and /or supporting laboratory results within the past 12 months. Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. Numerator: Indication: Routine 195,426 Numerator: Indication: Targeted 4 Numerator: Indication: Targeted 4 Numerator: Preg/BF by Indication: 14,533 Numerator: Preg/BF by Indication: 10 Breastfeeding Routine 0 Numerator: Preg/BF by Indication: 0 Pregnant Targeted 0 Numerator: Preg/BF by Indication: Breastfeeding Targeted 0 Numerator: Age/Sex by Indication: 1-9 Routine 1 Numerator: Age/Sex by Indication: 1-9 Routine 1 Numerator: Age/Sex by Indication: 15-19 Male Routine 1 Numerator: Age/Sex by Indication: 20-24 Male Routine 1 Numerator: Age/Sex by Indication: 22-49 Male Routine 1 Numerator: Age/Sex by Indication: 25-49 Male Routine 1 Numerator: Age/		
Number of adult and pediatric ART         patients with a viral load result         documented in the patient medical         record and /or laboratory records         in the past 12 months.         Numerator: Indication: Routine         195,426         Numerator: Indication: Targeted         4         Numerator: Preg/BF by Indication:         Pregnant Routine         Numerator: Preg/BF by Indication:         Breastfeeding Routine         Numerator: Preg/BF by Indication:         Pregnant Targeted         Numerator: Reg/BF by Indication:         Breastfeeding Targeted         Numerator: Age/Sex by Indication:         1-9 Routine         Numerator: Age/Sex by Indication:         1-9 Routine         Numerator: Age/Sex by Indication:         10-14 Male Routine         Numerator: Age/Sex by Indication:         15-19 Male Routine         Numerator: Age/Sex by Indication:         20-24 Male Routine         Numerator: Age/Sex by Indication:         20-24 Male Routine         Numerator: Age/Sex by Indication:         20-24 Male Routine         Numerator: Age/Sex by Indication:         25-49 Male Routine         Numerator: Age/Sex by Indication: <td></td> <td></td>		
Numerator: Indication: Routine195,426Numerator: Indication: Targeted4Numerator: Preg/BF by Indication: Pregnant Routine14,533Numerator: Preg/BF by Indication: Breastfeeding Routine10Numerator: Preg/BF by Indication: Pregnant Targeted0Numerator: Preg/BF by Indication: Breastfeeding Targeted0Numerator: Age/Sex by Indication: c 1 Routine0Numerator: Age/Sex by Indication: c 1 Routine10Numerator: Age/Sex by Indication: c 2 Routine10Nu	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records	216,985
Numerator:Indication:Targeted4Numerator:Preg/BF by Indication:14,533Pregnant Routine10Numerator:Preg/BF by Indication:10Breastfeeding Routine0Numerator:Preg/BF by Indication:0Pregnant Targeted0Numerator:Preg/BF by Indication:Breastfeeding Targeted0Numerator:Age/Sex by Indication:<1 Routine	· · ·	195,426
Numerator: Preg/BF by Indication: Pregnant Routine14,533Numerator: Preg/BF by Indication: Breastfeeding Routine10Numerator: Preg/BF by Indication: Pregnant Targeted0Numerator: Preg/BF by Indication: Breastfeeding Targeted0Numerator: Age/Sex by Indication: c 1 Routine0Numerator: Age/Sex by Indication: 1-9 Routine10Numerator: Age/Sex by Indication: 1-9 Routine10Numerator: Age/Sex by Indication: 1-9 Routine10Numerator: Age/Sex by Indication: 10-14 Male Routine10Numerator: Age/Sex by Indication: 15-19 Male Routine10Numerator: Age/Sex by Indication: 20-24 Male Routine10Numerator: Ag	Numerator: Indication: Targeted	
Breastfeeding Routine       10         Numerator: Preg/BF by Indication:       0         Pregnant Targeted       0         Numerator: Preg/BF by Indication:       0         Breastfeeding Targeted       0         Numerator: Age/Sex by Indication:       2         <1 Routine	Numerator: Preg/BF by Indication:	14,533
Pregnant Targeted       0         Numerator: Preg/BF by Indication:       1         Breastfeeding Targeted       1         Numerator: Age/Sex by Indication:       1         <1 Routine	- ·	10
Breastfeeding Targeted         Numerator: Age/Sex by Indication:         <1 Routine		0
<1 Routine	<b>U</b> ,	
1-9 RoutineNumerator: Age/Sex by Indication:10-14 Male RoutineNumerator: Age/Sex by Indication:15-19 Male RoutineNumerator: Age/Sex by Indication:20-24 Male RoutineNumerator: Age/Sex by Indication:25-49 Male RoutineNumerator: Age/Sex by Indication:25-49 Male RoutineNumerator: Age/Sex by Indication:50+ Male RoutineNumerator: Age/Sex by Indication:10-14 Female Routine		
10-14 Male RoutineNumerator: Age/Sex by Indication:15-19 Male RoutineNumerator: Age/Sex by Indication:20-24 Male RoutineNumerator: Age/Sex by Indication:25-49 Male RoutineNumerator: Age/Sex by Indication:50+ Male RoutineNumerator: Age/Sex by Indication:50+ Male RoutineNumerator: Age/Sex by Indication:10-14 Female Routine		
15-19 Male RoutineNumerator: Age/Sex by Indication: 20-24 Male RoutineNumerator: Age/Sex by Indication: 25-49 Male RoutineNumerator: Age/Sex by Indication: 50+ Male RoutineNumerator: Age/Sex by Indication: 10-14 Female Routine		
20-24 Male Routine         Numerator: Age/Sex by Indication:         25-49 Male Routine         Numerator: Age/Sex by Indication:         50+ Male Routine         Numerator: Age/Sex by Indication:         10-14 Female Routine		
25-49 Male Routine Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 10-14 Female Routine		
50+ Male Routine Numerator: Age/Sex by Indication: 10-14 Female Routine		
10-14 Female Routine		
Numerator: Age/Sex by Indication:		
	 Numerator: Age/Sex by Indication:	



	I
15-19 Female Routine	
Numerator: Age/Sex by Indication:	
20-24 Female Routine	
Numerator: Age/Sex by Indication:	
25-49 Female Routine	
Numerator: Age/Sex by Indication:	
50+ Female Routine	
Numerator: Age/Sex by Indication:	
<1 Targeted	
Numerator: Age/Sex by Indication:	
1-9 Targeted	
Numerator: Age/Sex by Indication:	
10-14 Male Targeted	
Numerator: Age/Sex by Indication:	
15-19 Male Targeted	
Numerator: Age/Sex by Indication:	
20-24 Male Targeted	
Numerator: Age/Sex by Indication:	
25-49 Male Targeted	
Numerator: Age/Sex by Indication:	
50+ Male Targeted	
Numerator: Age/Sex by Indication:	
10-14 Female Targeted	
Numerator: Age/Sex by Indication:	
15-19 Female Targeted	
Numerator: Age/Sex by Indication:	
20-24 Female Targeted	
Numerator: Age/Sex by Indication:	
25-49 Female Targeted	
Numerator: Age/Sex by Indication:	
50+ Female Targeted	
Numerator: Aggregate Age/Sex by	0
Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	3



Indication: 15+ Male TargetedNumerator: Aggregate Age/Sex by Indication: <15 Female TargetedNumerator: Aggregate Age/Sex by Indication: 15+ Female TargetedNumerator: Aggregate Age/Sex by Indication: <15 Male RoutineNumerator: Aggregate Age/Sex by Indication: 15+ Female RoutineNumerator: Aggregate Age/Sex by Indication: 15+ Female RoutineNumerator: Aggregate Age/Sex by Indication: 15+ Female RoutineDenominator: Indication: RoutineDenominator: Indication: RoutineDenominator: Indication: Targeted4Denominator: Preg/BF by Indication: Pregnant RoutineDenominator: Preg/BF by Indication: Pregnant TargetedDenominator: Preg/BF by Indication: Pregnant TargetedDenominator: Preg/BF by Indication: Preg/BF by Indication: Age/Sex by Indication: 1-9 RoutineDenominator: Age/Sex by Indication: 1-9 RoutineDenominator: Age/Sex by Indication: 10-14 Male RoutineDenominator: Age/Sex by Indication: 15-19 Male RoutineDenominator: Age/Sex by Indication: 20-24 Male RoutineDenominator: Age/Sex by Indication: 20-24 Male RoutineDenominator: Age/Sex by Indication: 20-24 Male Routine	· · · · · · · · · · · · · · · · · · ·	1
Indication: <15 Female Targeted0Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted1Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	Indication: 15+ Male Targeted	
Indication: <15 Female TargetedNumerator: Aggregate Age/Sex by Indication: 15+ Female Targeted1Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	Numerator: Aggregate Age/Sex by	0
Indication: 15+ Female Targeted1Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	Indication: <15 Female Targeted	U
Indication: 15+ Female TargetedNumerator: Aggregate Age/Sex by Indication: <15 Male Routine	Numerator: Aggregate Age/Sex by	1
Jication: <15 Male Routine3,838merator: Aggregate Age/Sex by dication: 15+ Male Routine73,657merator: Aggregate Age/Sex by dication: <15 Female Routine	lication: 15+ Female Targeted	I
Indication: <15 Male Routine	Jumerator: Aggregate Age/Sex by	2 9 2 9
dication: 15+ Male Routine73,657umerator: Aggregate Age/Sex by dication: <15 Female Routine	dication: <15 Male Routine	3,030
Indication: 15+ Male Routine         Iumerator: Aggregate Age/Sex by         Iumerator: Aggregate Age/Sex by         Iumerator: Aggregate Age/Sex by         Iumerator: Aggregate Age/Sex by         Indication: 15+ Female Routine         Denominator: Indication: Routine         Denominator: Indication: Targeted         Denominator: Preg/BF by         Indication: Pregnant Routine         Denominator: Preg/BF by         Indication: Pregnant Routine         Denominator: Preg/BF by         Indication: Pregnant Targeted         Denominator: Preg/BF by         Indication: Pregnant Targeted         Denominator: Preg/BF by         Indication: Breastfeeding Targeted         Denominator: Age/Sex by         Indication: Age/Sex by         Indication: 1-9 Routine         Denominator: Age/Sex by         Indication: 10-14 Male Routine         Denominator: Age/Sex by         Indication: 15-19 Male Routine         Denominator: Age/Sex by         Indication: 15-19 Male Routine	lumerator: Aggregate Age/Sex by	73 657
dication: <15 Female Routine	dication: 15+ Male Routine	10,001
Indication: <15 Female Routine	Numerator: Aggregate Age/Sex by	3 820
ndication: 15+ Female Routine       114,098         renominator: Indication: Routine       216,981         renominator: Indication: Targeted       4         renominator: Preg/BF by       16,366         renominator: Preg/BF by       11         renominator: Preg/BF by       11         renominator: Preg/BF by       0         renominator: Age/Sex	ndication: <15 Female Routine	5,023
Indication: 15+ Female Routine       216,981         Denominator: Indication: Targeted       4         Denominator: Preg/BF by       16,366         Indication: Pregnant Routine       11         Denominator: Preg/BF by       11         Indication: Breastfeeding Routine       0         Denominator: Preg/BF by       0         Indication: Pregnant Targeted       0         Denominator: Preg/BF by       0         Indication: Pregnant Targeted       0         Denominator: Preg/BF by       0         Indication: Breastfeeding Targeted       0         Denominator: Age/Sex by       0         Indication: <1 Routine	Numerator: Aggregate Age/Sex by	114 008
Denominator: Indication: Targeted4Denominator: Preg/BF by ndication: Pregnant Routine16,366Denominator: Preg/BF by ndication: Breastfeeding Routine11Denominator: Preg/BF by ndication: Pregnant Targeted0Denominator: Preg/BF by ndication: Pregnant Targeted0Denominator: Preg/BF by ndication: Breastfeeding Targeted0Denominator: Age/Sex by ndication: 1-9 Routine0Denominator: Age/Sex by ndication: 10-14 Male Routine0Denominator: Age/Sex by ndication: 15-19 Male Routine0Denominator: Age/Sex by ndication: 20-24 Male Routine0	ndication: 15+ Female Routine	117,000
Denominator: Preg/BF by16,366Indication: Pregnant Routine11Denominator: Preg/BF by11Indication: Breastfeeding Routine0Denominator: Preg/BF by0Indication: Pregnant Targeted0Denominator: Preg/BF by0Indication: Breastfeeding Targeted0Denominator: Age/Sex by0Indication: 1-9 Routine0Denominator: Age/Sex by1Indication: 10-14 Male Routine0Denominator: Age/Sex by1Indication: 15-19 Male Routine0Denominator: Age/Sex by0Indication: 15-19 Male Routine0Denominator: Age/Sex by0Indication: 15-19 Male Routine0Denominator: Age/Sex by0Indication: 20-24 Male Routine0	Denominator: Indication: Routine	216,981
Indication: Pregnant Routine16,366Denominator: Preg/BF by ndication: Breastfeeding Routine11Denominator: Preg/BF by ndication: Pregnant Targeted0Denominator: Preg/BF by ndication: Breastfeeding Targeted0Denominator: Preg/BF by ndication: Breastfeeding Targeted0Denominator: Age/Sex by ndication: <1 Routine	Denominator: Indication: Targeted	4
Indication: Pregnant Routine Denominator: Preg/BF by Indication: Breastfeeding Routine Denominator: Preg/BF by Indication: Pregnant Targeted Denominator: Preg/BF by Indication: Breastfeeding Targeted Denominator: Age/Sex by Indication: <1 Routine Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Denominator: Preg/BF by	16.266
11       11         Denominator: Preg/BF by       0         Denominator: Preg/BF by       0         Denominator: Preg/BF by       0         Denominator: Preg/BF by       0         Denominator: Breastfeeding Targeted       0         Denominator: Age/Sex by       0         ndication:        11         Denominator: Age/Sex by       0         ndication:        11         Denominator: Age/Sex by       0         ndication:        11         Denominator: Age/Sex by       0         ndication:        1.1         Denominator: Age/Sex by       0         ndication:        1.1         Denominator: Age/Sex by       0         ndication:        1.9 Routine         Denominator: Age/Sex by       0         ndication:        10-14 Male Routine         Denominator: Age/Sex by       0         ndication:        15-19 Male Routine         Denominator: Age/Sex by       0         ndication:        20-24 Male Routine	ndication: Pregnant Routine	10,300
Indication: Breastfeeding Routine         Denominator: Preg/BF by       0         Indication: Pregnant Targeted       0         Denominator: Preg/BF by       0         Indication: Breastfeeding Targeted       0         Denominator: Age/Sex by       0         Indication: <1 Routine	Denominator: Preg/BF by	4.4
0       0         Denominator: Preg/BF by       0         Denominator: Breastfeeding Targeted       0         Denominator: Age/Sex by       0         Denominator: 20-24 Male Routine       0	ndication: Breastfeeding Routine	11
Indication: Pregnant Targeted         Denominator: Preg/BF by       0         Indication: Breastfeeding Targeted       0         Denominator: Age/Sex by       1         Indication: <1 Routine	Denominator: Preg/BF by	0
0     0       Denominator: Age/Sex by     0       ndication: <1 Routine	ndication: Pregnant Targeted	U
Indication: Breastfeeding Targeted         Denominator: Age/Sex by         Indication: <1 Routine	Denominator: Preg/BF by	0
Indication: <1 Routine Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Indication: Breastfeeding Targeted	U
Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Denominator: Age/Sex by	
ndication: 1-9 Routine Denominator: Age/Sex by ndication: 10-14 Male Routine Denominator: Age/Sex by ndication: 15-19 Male Routine Denominator: Age/Sex by ndication: 20-24 Male Routine	ndication: <1 Routine	
Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	Denominator: Age/Sex by	
ndication: 10-14 Male Routine Denominator: Age/Sex by ndication: 15-19 Male Routine Denominator: Age/Sex by ndication: 20-24 Male Routine	ndication: 1-9 Routine	
Denominator: Age/Sex by ndication: 15-19 Male Routine Denominator: Age/Sex by ndication: 20-24 Male Routine	Denominator: Age/Sex by	
ndication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine	ndication: 10-14 Male Routine	
Denominator: Age/Sex by Indication: 20-24 Male Routine	Denominator: Age/Sex by	
ndication: 20-24 Male Routine	ndication: 15-19 Male Routine	
	Denominator: Age/Sex by	
enominator: Age/Sex by	ndication: 20-24 Male Routine	
	enominator: Age/Sex by	



Indication: 25-49 Male Routine Denominator: Age/Sex by Indication: 50+ Male Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 25-49 Female Routine Denominator: Age/Sex by Indication: 50+ Female Routine Denominator: Age/Sex by Indication: - 1 Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 50+ Female Tar
Indication: 50+ Male Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 25-49 Female Routine Denominator: Age/Sex by Indication: 50+ Female Routine Denominator: Age/Sex by Indication: 41 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: 20-24 Male Targeted Denominator: 20-24 Male Targeted Den
Denominator: Age/Sex by         Indication: 10-14 Female Routine         Denominator: Age/Sex by         Indication: 15-19 Female Routine         Denominator: Age/Sex by         Indication: 20-24 Female Routine         Denominator: Age/Sex by         Indication: 25-49 Female Routine         Denominator: Age/Sex by         Indication: 50+ Female Routine         Denominator: Age/Sex by         Indication: 50+ Female Routine         Denominator: Age/Sex by         Indication: 10+ Female Routine         Denominator: Age/Sex by         Indication: 10+ Targeted         Denominator: Age/Sex by         Indication: 10+ Male Targeted         Denominator: Age/Sex by         Indication: 10+ Male Targeted         Denominator: Age/Sex by         Indication: 20-24 Male Targeted         Denominator: Age/Sex by         Indication: 20+ Male Targeted         Denominator: Age/Sex by         Indication: 20+ Male Targeted         Denominator: Age/Sex by         Indication: 20+ Male Targeted         Denominator: Age/Sex by         Indication: 50+ Male Targeted         Denominator: Age/Sex by         Indication: 50+ Male Targeted         Denominator: Age/Sex by
Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 25-49 Female Routine Denominator: Age/Sex by Indication: 50+ Female Routine Denominator: Age/Sex by Indication: -1 Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted
Denominator: Age/Sex by Indication: 15-19 Female RoutineDenominator: Age/Sex by Indication: 20-24 Female RoutineDenominator: Age/Sex by Indication: 25-49 Female RoutineDenominator: Age/Sex by Indication: 50+ Female RoutineDenominator: Age/Sex by Indication: <1 Targeted
Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 25-49 Female Routine Denominator: Age/Sex by Indication: 50+ Female Routine Denominator: Age/Sex by Indication: <1 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 60+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted
Denominator: Age/Sex by Indication: 20-24 Female RoutineDenominator: Age/Sex by Indication: 25-49 Female RoutineDenominator: Age/Sex by Indication: 50+ Female RoutineDenominator: Age/Sex by Indication: 41 TargetedDenominator: Age/Sex by Indication: 1-9 TargetedDenominator: Age/Sex by Indication: 10-14 Male TargetedDenominator: Age/Sex by Indication: 15-19 Male TargetedDenominator: Age/Sex by Indication: 20-24 Male TargetedDenominator: Age/Sex by Indication: 25-49 Male TargetedDenominator: Age/Sex by Indication: 50+ Male TargetedDenominator: Age/Sex by Indication: 50+ Male TargetedDenominator: Age/Sex by Indication: 10-14 Female Targeted
Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 25-49 Female Routine Denominator: Age/Sex by Indication: 50+ Female Routine Denominator: Age/Sex by Indication: <1 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted
Denominator: Age/Sex by         Indication: 25-49 Female Routine         Denominator: Age/Sex by         Indication: 50+ Female Routine         Denominator: Age/Sex by         Indication: <1 Targeted
Indication: 25-49 Female RoutineDenominator: Age/Sex byIndication: 50+ Female RoutineDenominator: Age/Sex byIndication: <1 Targeted
Indication: 25-49 Female Routine         Denominator: Age/Sex by         Indication: 50+ Female Routine         Denominator: Age/Sex by         Indication: <1 Targeted
Indication: 50+ Female RoutineDenominator: Age/Sex byIndication: <1 Targeted
Denominator: Age/Sex byIndication: <1 Targeted
Indication: <1 TargetedDenominator: Age/Sex byIndication: 1-9 TargetedDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 25-49 Male TargetedDenominator: Age/Sex byIndication: 50+ Male TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 10-14 Female Targeted
Denominator: Age/Sex byIndication: 1-9 TargetedDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 25-49 Male TargetedDenominator: Age/Sex byIndication: 50+ Male TargetedDenominator: Age/Sex byIndication: 50+ Male TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female Targeted
Indication: 1-9 TargetedDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 25-49 Male TargetedDenominator: Age/Sex byIndication: 50+ Male TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 50+ Male TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female Targeted
Denominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 25-49 Male TargetedDenominator: Age/Sex byIndication: 50+ Male TargetedDenominator: Age/Sex byIndication: 10-14 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female Targeted
Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted
Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by
Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by
Indication: 20-24 Male Targeted Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Denominator: Age/Sex by Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Indication: 25-49 Male Targeted Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Denominator: Age/Sex by Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Indication: 50+ Male Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 15-19 Female Targeted
Denominator: Age/Sex by Indication: 15-19 Female Targeted
Indication: 15-19 Female Targeted
Denominator: Age/Sex by
Indication: 20-24 Female Targeted
Denominator: Age/Sex by



Indication: 25-49 Female Targeted         Denominator: Age/Sex by         Indication: 50+ Female Targeted         Denominator: Aggregate Age/Sex         by Indication: <15 Male Targeted         Denominator: Aggregate Age/Sex         by Indication: 15+ Male Targeted         Denominator: Aggregate Age/Sex         by Indication: <15 Female Targeted         Denominator: Aggregate Age/Sex         by Indication: <15 Female Targeted         Denominator: Aggregate Age/Sex         by Indication: <15 Female Targeted         Denominator: Aggregate Age/Sex         by Indication: <15 Hale Routine         Denominator: Aggregate Age/Sex         by Indication: <15 Male Routine         Denominator: Aggregate Age/Sex         by Indication: <15 Female Routine         Denominator: Aggregate Age/Sex         by Indication: <15 Female Routine         Denominator: Aggregate Age/Sex         by Indication: <15 Female Routine         Numerator Aggregated Age/Sex:         <15 Male         Numerator Aggregated Age/Sex:         <15 Female         Numerator Aggregated Age/Sex:         <15 Female         Denominator Aggregated Age/Sex:         <15 Female         Denominator Aggregated Age/Sex:																																																																																																																																				
Indication: 50+ Female Targeted         Denominator: Aggregate Age/Sex         by Indication: <15 Male Targeted		Indication: 25-49 Female Targeted																																																																																																																																		
Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted0Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted3Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted		Denominator: Age/Sex by		by Indication: <15 Male Targeted		Indication: 50+ Female Targeted		by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15+ Male Numerator Aggregated Age/Sex: <15+ Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	0	by Indication: 15+ Male Targeted       3         Denominator: Aggregate Age/Sex       0         by Indication: <15 Female Targeted		by Indication: <15 Male Targeted	0	by Indication: 15+ Male TargetedDenominator: Aggregate Age/Sexby Indication: <15 Female Targeted		Denominator: Aggregate Age/Sex	0	by Indication: <15 Female Targeted0Denominator: Aggregate Age/Sex1by Indication: 15+ Female Targeted1Denominator: Aggregate Age/Sex4,232by Indication: <15 Male Routine		by Indication: 15+ Male Targeted	3	by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male		Denominator: Aggregate Age/Sex	0	by Indication: 15+ Female Targeted1Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	<126,228		by Indication: <15 Female Targeted	0	by Indication: 15+ Female TargetedDenominator: Aggregate Age/Sexby Indication: <15 Male Routine		Denominator: Aggregate Age/Sex	4	by Indication: <15 Male Routine		by Indication: 15+ Female Targeted	I	by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex:		Denominator: Aggregate Age/Sex	4 000	by Indication: 15+ Male Routine82,284Denominator: Aggregate Age/Sex by Indication: <15 Female Routine		by Indication: <15 Male Routine	4,232	by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	00.004	by Indication: <15 Female Routine		by Indication: 15+ Male Routine	82,284	by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	4 000	by Indication: 15+ Female Routine       126,228         Numerator Aggregated Age/Sex:          <15 Male		by Indication: <15 Female Routine	4,223	by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Male		Denominator: Aggregate Age/Sex	100.000	<15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		by Indication: 15+ Female Routine	126,228	Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		Numerator Aggregated Age/Sex:		15+ Male         Numerator Aggregated Age/Sex:         <15 Female		<15 Male		Numerator Aggregated Age/Sex:         <15 Female		Numerator Aggregated Age/Sex:		<15 Female <table>         &lt;15 Female</table>		15+ Male		Numerator Aggregated Age/Sex:         15+ Female         Denominator Aggregated Age/Sex:         <15 Male		Numerator Aggregated Age/Sex:		15+ Female         Denominator Aggregated Age/Sex:         <15 Male		<15 Female		15+ Female         Denominator Aggregated Age/Sex:         <15 Male		Numerator Aggregated Age/Sex:		<15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female				<15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		Denominator Aggregated Age/Sex:		15+ Male Denominator Aggregated Age/Sex: <15 Female		<15 Male		15+ Male Denominator Aggregated Age/Sex: <15 Female		Denominator Aggregated Age/Sex:		<15 Female				<15 Female		Denominator Aggregated Age/Sex:		Denominator Aggregated Age/Sex:					F	Denominator Aggregated Age/Sex:	
	Denominator: Age/Sex by		by Indication: <15 Male Targeted		Indication: 50+ Female Targeted		by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15+ Male Numerator Aggregated Age/Sex: <15+ Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	0	by Indication: 15+ Male Targeted       3         Denominator: Aggregate Age/Sex       0         by Indication: <15 Female Targeted		by Indication: <15 Male Targeted	0	by Indication: 15+ Male TargetedDenominator: Aggregate Age/Sexby Indication: <15 Female Targeted		Denominator: Aggregate Age/Sex	0	by Indication: <15 Female Targeted0Denominator: Aggregate Age/Sex1by Indication: 15+ Female Targeted1Denominator: Aggregate Age/Sex4,232by Indication: <15 Male Routine		by Indication: 15+ Male Targeted	3	by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male		Denominator: Aggregate Age/Sex	0	by Indication: 15+ Female Targeted1Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	<126,228		by Indication: <15 Female Targeted	0	by Indication: 15+ Female TargetedDenominator: Aggregate Age/Sexby Indication: <15 Male Routine		Denominator: Aggregate Age/Sex	4	by Indication: <15 Male Routine		by Indication: 15+ Female Targeted	I	by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex:		Denominator: Aggregate Age/Sex	4 000	by Indication: 15+ Male Routine82,284Denominator: Aggregate Age/Sex by Indication: <15 Female Routine		by Indication: <15 Male Routine	4,232	by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	00.004	by Indication: <15 Female Routine		by Indication: 15+ Male Routine	82,284	by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	4 000	by Indication: 15+ Female Routine       126,228         Numerator Aggregated Age/Sex:          <15 Male		by Indication: <15 Female Routine	4,223	by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Male		Denominator: Aggregate Age/Sex	100.000	<15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		by Indication: 15+ Female Routine	126,228	Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		Numerator Aggregated Age/Sex:		15+ Male         Numerator Aggregated Age/Sex:         <15 Female		<15 Male		Numerator Aggregated Age/Sex:         <15 Female		Numerator Aggregated Age/Sex:		<15 Female <table>         &lt;15 Female</table>		15+ Male		Numerator Aggregated Age/Sex:         15+ Female         Denominator Aggregated Age/Sex:         <15 Male		Numerator Aggregated Age/Sex:		15+ Female         Denominator Aggregated Age/Sex:         <15 Male		<15 Female		15+ Female         Denominator Aggregated Age/Sex:         <15 Male		Numerator Aggregated Age/Sex:		<15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female				<15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		Denominator Aggregated Age/Sex:		15+ Male Denominator Aggregated Age/Sex: <15 Female		<15 Male		15+ Male Denominator Aggregated Age/Sex: <15 Female		Denominator Aggregated Age/Sex:		<15 Female				<15 Female		Denominator Aggregated Age/Sex:		Denominator Aggregated Age/Sex:					F	Denominator Aggregated Age/Sex:		
	Denominator: Age/Sex by																																																																																																																																			
by Indication: <15 Male Targeted		Indication: 50+ Female Targeted																																																																																																																																		
by Indication: <15 Male Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15+ Male Numerator Aggregated Age/Sex: <15+ Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	0																																																																																																																																	
by Indication: 15+ Male Targeted       3         Denominator: Aggregate Age/Sex       0         by Indication: <15 Female Targeted		by Indication: <15 Male Targeted	0																																																																																																																																	
by Indication: 15+ Male TargetedDenominator: Aggregate Age/Sexby Indication: <15 Female Targeted		Denominator: Aggregate Age/Sex	0																																																																																																																																	
by Indication: <15 Female Targeted0Denominator: Aggregate Age/Sex1by Indication: 15+ Female Targeted1Denominator: Aggregate Age/Sex4,232by Indication: <15 Male Routine		by Indication: 15+ Male Targeted	3																																																																																																																																	
by Indication: <15 Female Targeted Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted Denominator: Aggregate Age/Sex by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male		Denominator: Aggregate Age/Sex	0																																																																																																																																	
by Indication: 15+ Female Targeted1Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	<126,228		by Indication: <15 Female Targeted	0																																																																																																																																
by Indication: 15+ Female TargetedDenominator: Aggregate Age/Sexby Indication: <15 Male Routine		Denominator: Aggregate Age/Sex	4																																																																																																																																	
by Indication: <15 Male Routine		by Indication: 15+ Female Targeted	I																																																																																																																																	
by Indication: <15 Male Routine Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex:		Denominator: Aggregate Age/Sex	4 000																																																																																																																																	
by Indication: 15+ Male Routine82,284Denominator: Aggregate Age/Sex by Indication: <15 Female Routine		by Indication: <15 Male Routine	4,232																																																																																																																																	
by Indication: 15+ Male Routine Denominator: Aggregate Age/Sex by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	00.004																																																																																																																																	
by Indication: <15 Female Routine		by Indication: 15+ Male Routine	82,284																																																																																																																																	
by Indication: <15 Female Routine Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female		Denominator: Aggregate Age/Sex	4 000																																																																																																																																	
by Indication: 15+ Female Routine       126,228         Numerator Aggregated Age/Sex:          <15 Male		by Indication: <15 Female Routine	4,223																																																																																																																																	
by Indication: 15+ Female Routine Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Male		Denominator: Aggregate Age/Sex	100.000																																																																																																																																	
<15 Male Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		by Indication: 15+ Female Routine	126,228																																																																																																																																	
Numerator Aggregated Age/Sex: 15+ Male Numerator Aggregated Age/Sex: <15 Female Numerator Aggregated Age/Sex: 15+ Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		Numerator Aggregated Age/Sex:																																																																																																																																		
15+ Male         Numerator Aggregated Age/Sex:         <15 Female		<15 Male																																																																																																																																		
Numerator Aggregated Age/Sex:         <15 Female		Numerator Aggregated Age/Sex:																																																																																																																																		
<15 Female <table>         &lt;15 Female</table>		15+ Male																																																																																																																																		
Numerator Aggregated Age/Sex:         15+ Female         Denominator Aggregated Age/Sex:         <15 Male		Numerator Aggregated Age/Sex:																																																																																																																																		
15+ Female         Denominator Aggregated Age/Sex:         <15 Male		<15 Female																																																																																																																																		
15+ Female         Denominator Aggregated Age/Sex:         <15 Male		Numerator Aggregated Age/Sex:																																																																																																																																		
<15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female																																																																																																																																				
<15 Male Denominator Aggregated Age/Sex: 15+ Male Denominator Aggregated Age/Sex: <15 Female		Denominator Aggregated Age/Sex:																																																																																																																																		
15+ Male Denominator Aggregated Age/Sex: <15 Female		<15 Male																																																																																																																																		
15+ Male Denominator Aggregated Age/Sex: <15 Female		Denominator Aggregated Age/Sex:																																																																																																																																		
<15 Female																																																																																																																																				
<15 Female		Denominator Aggregated Age/Sex:																																																																																																																																		
Denominator Aggregated Age/Sex:																																																																																																																																				
	F	Denominator Aggregated Age/Sex:																																																																																																																																		



15+ Female	
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	0
<15, Undocumented Test Indication, Male	0
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0
15+, Undocumented Test Indication, Female	0
15+, Undocumented Test Indication, Male	0
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	
Unknown Age, Routine, Male	
Unknown Age, Routine, Unknown Sex	
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	
Unknown Age, Undocumented Test Indication, Female	0
Unknown Age, Undocumented Test Indication, Male	0
Unknown Age, Undocumented Test Indication, Unknown Sex	
Breastfeeding, Undocumented Test Indication	0



Pregnant, Undocumented Test Indication	0
Undocumented Test Indication	0
<15, Routine, Unknown Sex	0
<15, Targeted, Unknown Sex	0
<15, Undocumented Test Indication, Female	0
<15, Undocumented Test Indication, Male	0
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	0
15+, Targeted, Unknown Sex	0
15+, Undocumented Test Indication, Female	0
15+, Undocumented Test Indication, Male	0
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	
Unknown Age, Routine, Male	
Unknown Age, Routine, Unknown Sex	
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	
Unknown Age, Undocumented Test Indication, Female	
Unknown Age, Undocumented Test Indication, Male	
Unknown Age, Undocumented Test Indication, Unknown Sex	



	Breastfeeding, Undocumented Test	
	Indication	
	Pregnant, Undocumented Test Indication	27
	Undocumented Test Indication	0
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	90 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	46,596
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	51,698
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	



Age/Sed: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 50+ Female (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
·	



Age/Sex: >1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	



those who have stopped ART, and
those lost to follow-up)
Age/Sex: 25-49 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 50+ Male (Denominator:
Total number of adults and children
who initiated ART in the 12 months
prior to the beginning of the
reporting period, including those
who have died, those who have
stopped ART, and those lost to
follow-up)
Age/Sex: 10-14 Female
Age/Sex: 10-14 Female (Denominator: Total number of
_
(Denominator: Total number of
(Denominator: Total number of adults and children who initiated
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)



a	adults and children who initiated
A	ART in the 12 months prior to the
b	beginning of the reporting period,
in	ncluding those who have died,
th	hose who have stopped ART, and
th	hose lost to follow-up)
A	Age/Sex: 25-49 Female
([	Denominator: Total number of
30	adults and children who initiated
A	ART in the 12 months prior to the
b	beginning of the reporting period,
in	ncluding those who have died,
th	hose who have stopped ART, and
th	hose lost to follow-up)
A	Age/Sex: 50+ Female
(E	Denominator: Total number of
a	adults and children who initiated
A	ART in the 12 months prior to the
b	beginning of the reporting period,
in	ncluding those who have died,
th	hose who have stopped ART, and
th	hose lost to follow-up)
A	Aggregated Age: <15 (Numerator:
Ν	Number of adults and children who
a	are still alive and on treatment at
1:	2 months after initiating ART)
A	Aggregated Age: 15+ (Numerator:
Ν	Number of adults and children who
a	are still alive and on treatment at
1:	2 months after initiating ART)
A	Aggregated Age: <15
	Denominator: Total number of
à	adults and children who initiated
A	ART in the 12 months prior to the
	beginning of the reporting period,
	ncluding those who have died,



those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	2,679
Numerator by Status: Breastfeeding	10
Denominator by Status: Pregnant	2,961
Denominator by Status:	
Breastfeeding	11
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	376
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,011
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	368
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	27,834



	initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	389
	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,007
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	379
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30,922
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a	1



result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	
By Graduates: Doctors	
By Graduates: Nurses	
By Graduates: Midwives	
By Graduates: Social service workers	
By Graduates: Laboratory professionals	
By Graduates: Other	1
Sum of Graduates disaggreagtes	1



# Partners and Implementing Mechanisms

#### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7455	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
11018	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	99,161
11030	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
13981	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14301	Population Services International	NGO	U.S. Agency for International Development	GHP-State	2,983,756
16766	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	0
16768	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-USAID	0
17123	Columbia University	University	U.S. Department of Health and Human	GHP-State	830,000



17429	Services International	NGO	U.S. Department of Defense	GHP-State	270,503
17429		NGO Private Contractor	of Defense U.S. Department of Health and Human	GHP-State GHP-State	270,503 1,310,000
			Control and Prevention		
17432	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,199,199
17549	JHPIEGO	University	U.S. Agency for International Development	GHP-State	3,312,197
18020	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	12,945,811
	Global Health		U.S. Agency for		2,000,000



	Program		Development		
18143	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	2,040,131
18227	TBD	твр	Redacted	Redacted	Redacted
18235	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-USAID	1,250,000
18240	Vodafone Foundation	NGO	U.S. Agency for International Development	GHP-USAID	0
18524	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18525	Baylor College of Medicine Children's Foundation	University	U.S. Agency for International Development	GHP-State	1,000,000
18641	TBD	TBD	Redacted	Redacted	Redacted
18642	TBD	TBD	Redacted	Redacted	Redacted
18643	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State, GHP- USAID	500,000



# Implementing Mechanism(s)

### Implementing Mechanism Details

Mechanism ID: 7455	Mechanism Name: LDF, Department of Defense Support		
Funding Agency: DOD	Procurement Type: Grant		
Prime Partner Name: U.S. Department of Defense (	Defense)		
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source	Funding Amount		
GHP-State	0		

# Cross-Cutting Budget Attribution(s)

(No data provided.)

## **Budget Code Information**

Mechanism ID:	7455			
Mechanism Name:	LDF, Department of Defense Support			
Prime Partner Name:	U.S. Department of Defe	U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and	HVSI	0	0	



# Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 11018	Mechanism Name: Peace Corps		
Funding Agency: PC	Procurement Type: USG Core		
Prime Partner Name: U.S. Peace Corps			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
Total All Funding Sources: 99,161	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 37,839			
Total All Funding Sources and Applied Pipeline Amount: 137,000			
Funding Source	Funding Amount		
GHP-State	99,161		

#### Cross-Cutting Budget Attribution(s)

Gender: GBV	10,250
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	10,250
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Education	10,250
Water	10,000



### **Budget Code Information**

Mechanism ID:	11018		
Mechanism Name:	Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	44,161	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,997
PP_PREV_TA	Age/sex: 10-14 Male	394
PP_PREV_TA	Age/sex: 15-19 Male	283
PP_PREV_TA	Age/sex: 20-24 Male	150
PP_PREV_TA	Age/sex: 25-49 Male	33
PP_PREV_TA	Age/sex: 50+ Male	9
PP_PREV_TA	Age/sex: 10-14 Female	479
PP_PREV_TA	Age/sex: 15-19 Female	435
PP_PREV_TA	Age/sex: 20-24 Female	138
PP_PREV_TA	Age/sex: 25-49 Female	55
PP_PREV_TA	Age/sex: 50+ Female	18
PP_PREV_TA	Sum of Age/Sex disaggregates	1,994
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,258



		1
OVC_SERV_TA	Age/Sex: 10-14 Male	248
OVC_SERV_TA	Age/Sex: 15-17 Male	198
OVC_SERV_TA	By age/sex: 18-24 Male	88
OVC_SERV_TA	By age/sex: 25+ Male	6
OVC_SERV_TA	Age/Sex: 10-14 Female	291
OVC_SERV_TA	Age/Sex: 15-17 Female	251
OVC_SERV_TA	By age/sex: 18-24 Female	84
OVC_SERV_TA	By age/sex: 25+ Female	11
OVC_SERV_TA	Sum of Age/Sex disaggregates	988
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	55
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	46
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	33
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	13
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10- 14	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15- 17	111
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18- 24	48



r		
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	111
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	48
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	282
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	34
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	27
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	10
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	19
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	16
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	2
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	86
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	111
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	38
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	0



OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	111
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	38
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	348
OVC_SERV_TA	OVC_SERV_TA Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	71
OVC_SERV_TA	OVC_SERV_TA Required only for DREAMS countries: By Service Area age and sex: Other Service Areas Female 18-24	
OVC_SERV_TA age and sex: Other Service Areas Female		0
OVC_SERV_TA	OVC_SERV_TA Age/Sex: <1	
OVC_SERV_TA Age/Sex: 1-9		81
OVC_SERV_TA	Program Completion: Active	1,258
OVC_SERV_TA	OVC_SERV_TA Required only for DREAMS countries: By Service Areas Male 10-14	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	26
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	217

# Implementing Mechanism Details

Mechanism ID: 11030	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
2G: No Managing Agency:			
ſ.			
Total All Funding Sources: 150,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 150,000			
Funding Source	Funding Amount		
GHP-State	150,000		

# Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	30,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Education	50,000
Food and Nutrition: Policy, Tools, and Service	100,000
Delivery	

# **Budget Code Information**

Mechanism ID:			
Mechanism Name:	PEPFAR Small Grants Program		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	30,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	60,000	0

#### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
	Number of active beneficiaries served by PEPFAR	620
OVC_SERV_DSD	OVC programs for children and families affected by HIV/AIDS	630
OVC_SERV_DSD	Age/Sex: 10-14 Male	121
OVC_SERV_DSD	Age/Sex: 15-17 Male	37
OVC_SERV_DSD	By: Age/sex: Male 18-24	18
OVC_SERV_DSD	By: Age/sex: Male 25+	43
OVC_SERV_DSD	Age/Sex: 10-14 Female	117
OVC_SERV_DSD	Age/Sex: 15-17 Female	39
OVC_SERV_DSD	By: Age/sex: 18-24 Female	14
OVC_SERV_DSD	By: Age/sex: 25+ Female	41
OVC_SERV_DSD	Sum of Age/Sex disaggregates	314
OVC_SERV_DSD	Age/Sex: <1	6
OVC_SERV_DSD	Age/Sex: 1-9	194
OVC_SERV_DSD	Program Completion: Active	630

### Implementing Mechanism Details

Mechanism ID: 13981	Mechanism Name: TARGET: Increasing access to HIV counseling, testing and enhancing HIV/AIDS prevention	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		



G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied	Pipeline Amount: 0	
Funding Source Funding Amount		
GHP-State	0	

(No data provided.)

#### **Budget Code Information**

Mechanism ID: Mechanism Name:	TARGET: Increasing access to HIV counseling, testing and enhancing		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 14301	Mechanism Name: LETLAMA	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 2,983,756	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,983,756		
Funding Source Funding Amount		
GHP-State	2,983,756	

Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education



Focus Area:	Equity in HIV prevention, care, treatment and
	support
Sub Area:	Capacity building
Sub Area:	Implementation
Condom programming	10,000

Mechanism ID: Mechanism Name:			
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVAB 100,000 0		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVOP	2,883,756	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	79,150
PP_PREV_DSD	Age/sex: 10-14 Male	1,548
PP_PREV_DSD	Age/sex: 15-19 Male	3,573
PP_PREV_DSD	Age/sex: 20-24 Male	5,030
PP_PREV_DSD	Age/sex: 25-49 Male	19,524
PP_PREV_DSD	Age/sex: 50+ Male	1,696
PP_PREV_DSD	Age/sex: 10-14 Female	18,525



PP_PREV_DSD	Age/sex: 15-19 Female	10,783
PP_PREV_DSD	Age/sex: 20-24 Female	11,917
PP_PREV_DSD	Age/sex: 25-49 Female	5,470
PP_PREV_DSD	Age/sex: 50+ Female	1,084
PP_PREV_DSD	Sum of Age/Sex disaggregates	79,150
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,599
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,131
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,468
GEND_GBV_DSD	Number of people receiving post-GBV care	2,750
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	278
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,469
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,234
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	25
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	222
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	98
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	893
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	20
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	97
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	97
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	881

Page 112 of 191

FACTS Info v3.8.21.10



GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	13
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	97
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence 19	
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	173
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence 2	
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care) 43	
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1

### Implementing Mechanism Details

Mechanism ID: 16766	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)
Funding Agency: USAID Procurement Type: Cooperative Agreemen	
Prime Partner Name: University Research Corporation	on, LLC
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

# Cross-Cutting Budget Attribution(s)

(No data provided.)

# Budget Code Information

Mechanism ID: 16766



	e: Applying Science to Strengthen and Improve Systems (ASSIST) e: University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

# Implementing Mechanism Indicator Information

Indicator Number	Label	2018
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_DSD	OVC programs for children and families affected by	48,647
	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	4,625
OVC_SERV_DSD	Age/Sex: 15-17 Male	5,735
OVC_SERV_DSD	By: Age/sex: Male 18-24	4,366
OVC_SERV_DSD	By: Age/sex: Male 25+	4,370
OVC_SERV_DSD	Age/Sex: 10-14 Female	4,233
OVC_SERV_DSD	Age/Sex: 15-17 Female	5,040
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,585
OVC_SERV_DSD	By: Age/sex: 25+ Female	4,974
OVC_SERV_DSD	Sum of Age/Sex disaggregates	19,633

Custom 2017-07-20 18:41 EDT Page 114 of 191

FACTS Info v3.8.21.10



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,391
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	895
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	259
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,379
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	891
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	165
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,520
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	1,054
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	356
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	2,391
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,497
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,030
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	404
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	1,037
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	2,308
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,405



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	327
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	530
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	2,367
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,314
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	314
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	199
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	34
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	95
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	623
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	6,057
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	35
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	102
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	457
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	1,768
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,798
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,213
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	550



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	3,847
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,667
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,288
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	401
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	993
OVC_SERV_DSD	Age/Sex: <1	2,685
OVC_SERV_DSD	Age/Sex: 1-9	9,035
OVC_SERV_DSD	Program Completion: Active	48,647

# Implementing Mechanism Details

Mechanism ID: 16768	Mechanism Name: Mentor Mothers Reducing Infections Through Support and Education (RISE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-USAID	0	

# Cross-Cutting Budget Attribution(s)

(No data provided.)



Mechanism ID: Mechanism Name: Prime Partner Name:	Mentor Mothers Reducin (RISE)	ng Infections Through Su	pport and Education
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	МТСТ	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 17123	Mechanism Name: CDC HMIS support to the MOH
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:	
Total All Funding Sources: 830,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0	Total Mechanism Fipeline. N/A	
Total All Funding Sources and Applied Pipeline Amount: 830,000		
Funding Source	Funding Amount	
GHP-State	830,000	

Human Resources for Health 75,000
-----------------------------------

#### Budget Code Information

	17123 CDC HMIS support to th Columbia University	е МОН	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	830,000	0

#### Implementing Mechanism Indicator Information

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 17401	Mechanism Name: Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 11,457,577	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 992,674		
Total All Funding Sources and Applied Pipeline Amount: 12,450,251		
Funding Source	Funding Amount	
GHP-State	11,457,577	

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	120,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and



	productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	150,000
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Water	200,000
Motor Vehicles: Purchased	110,283

Mechanism ID:	17401		
Mechanism Name:	Strengthening Tuberculosis and HIV Response in Lesotho (STAR-L)		
Prime Partner Name:	Elizabeth Glaser Pediatr	ic AIDS Foundation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	897,233	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,604,559	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	105,683	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,275,862	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	712,085	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	МТСТ	165,126	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,345,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	351,787	0

# Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,228
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,417
PMTCT_ART_DSD	New on ART	2,035
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,193
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,417
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,558
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,206
PMTCT_STAT_DSD	By Age (Denominator): 25-49	7,985
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	611



	1	
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,077
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,381
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	280
PMTCT_STAT_DSD	By Number of new positives: 20-24	486
PMTCT_STAT_DSD	By Number of new positives: 25-49	626
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,583
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,538
PMTCT_STAT_DSD	By Number of new negative: 25-49	5,835
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,469
PMTCT_STAT_DSD	By Age (Numerator): 20-24	6,098
PMTCT_STAT_DSD	By Age (Numerator): 25-49	7,850
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	4,741
PrEP_NEW_DSD	Male 15-19	345
PrEP_NEW_DSD	Male 20-24	326
PrEP_NEW_DSD	Male 25-49	1,113
PrEP_NEW_DSD	Male 50+	507
PrEP_NEW_DSD	Female 15-19	368
PrEP_NEW_DSD	Female 20-24	349
PrEP_NEW_DSD	Female 25-49	1,189
PrEP_NEW_DSD	Female 50+	544



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	320,407
HTC_TST_DSD	By Test Result: Positive	31,199
HTC_TST_DSD	Sum of Test Result disaggregates	31,199
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	186
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	172
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	511
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	258
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	3,877
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	382
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male,	2,531



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	250
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,029
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	595
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	6,221
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	6,330
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	427
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,902
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	260



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,221
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,267
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,602
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	631
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	69,812
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	9,575
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	45,077
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	6,167
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	19,040
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	2,623
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	11,341
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,562
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	2,242
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	20,192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	157
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,101



HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	126
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	186
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	556
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	279
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	4,211
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	567
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	2,731
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	371
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	1,136



	Negative		
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	152	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	676	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	89	
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	43	
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	394	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,447	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	9	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,474	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive		
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	851	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	97	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	521	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	58	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,512	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	276	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative		
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	135	



HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	18,934	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive 2,		
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	12,060	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,338	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	5,327	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	590	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,176	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	346	
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	523	
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	4,707	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	32	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,454	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	125	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,829	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	335	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	7,918	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	687	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0	



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,223
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,223
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	90
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,142
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	67
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,924
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	90
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,143
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	67
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,923
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	3,625



	during TB treatment during the reporting period		
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,625	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	64	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,187	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	43	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,331	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	64	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2,187	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	43	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	1,331	



	during the reporting period)		
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period         4,2		
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	10	
PMTCT_EID_DSD	Unknown, <= 2 months	0	
PMTCT_EID_DSD	Unknown, 2 - 12 months	0	
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	3,435	
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	21	
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	753	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	99,863	
TX_CURR_DSD	Age/Sex: 15-19 Male	1,109	
TX_CURR_DSD	Age/Sex: 15-19 Female	1,827	
TX_CURR_DSD	Sum of age/sex disaggregates	2,936	
TX_CURR_DSD	Age/Sex: <1	229	
TX_CURR_DSD	Age/Sex: <1-9	2,057	
TX_CURR_DSD	Age/Sex: 10-14 Male	654	
TX_CURR_DSD	Age/Sex: 10-14 Female	633	
TX_CURR_DSD	Age/Sex: 20-24 Male	2,749	
TX_CURR_DSD	Age/Sex: 25-49 Male	26,843	
TX_CURR_DSD	Age/Sex: 50+ Male	6,458	
TX_CURR_DSD	Age/Sex: 20-24 Female	5,426	
TX_CURR_DSD	Age/Sex: 25-49 Female	41,011	
TX_CURR_DSD	Age/Sex: 50+ Female	10,867	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)		
TX_NEW_DSD	By Age/Sex: <1	19	
TX_NEW_DSD	By Age/Sex: 1-9	228	
TX_NEW_DSD	By Age/Sex: 10-14 Male 7		

Page 132 of 191

FACTS Info v3.8.21.10



TX_NEW_DSD	By Age/Sex: 15-19 Male	488
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,202
TX_NEW_DSD	By Age/Sex: 25-49 Male	11,783
TX_NEW_DSD	By Age/Sex: 50+ Male	2,860
TX_NEW_DSD	By Age/Sex: 10-14 Female	70
TX_NEW_DSD	By Age/Sex: 15-19 Female	801
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,379
TX_NEW_DSD	By Age/Sex: 25-49 Female	18,038
TX_NEW_DSD	By Age/Sex: 50+ Female	4,806
TX_NEW_DSD	Sum of Age/Sex disaggregates	42,503
TX_NEW_DSD	Pregnancy status	2,026
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	72,555
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	80,648
TX_PVLS_DSD	Numerator: Indication: Routine	72,555
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	2,951
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male	26,962



	Routine		
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,485	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	42,596	
TX_PVLS_DSD	Denominator: Indication: Routine	80,648	
TX_PVLS_DSD	Denominator: Indication: Targeted	0	
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	3,521	
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0	
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0	
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	+ 0	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,670	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	30,486	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,650	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	46,828	
TX_PVLS_DSD	<15, Routine, Unknown Sex	0	
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0	
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0	
TX_PVLS_DSD	<15, Undocumented Test Indication, Male		



<15, Undocumented Test Indication, Unknown Sex	0	
15+, Routine, Unknown Sex	0	
15+, Targeted, Unknown Sex	0	
15+, Undocumented Test Indication, Female	0	
15+, Undocumented Test Indication, Male	0	
15+, Undocumented Test Indication, Unknown Sex	0	
Unknown Age, Targeted, Female	0	
Unknown Age, Targeted, Male	0	
Unknown Age, Undocumented Test Indication, Female	0	
Unknown Age, Undocumented Test Indication, Male	0	
Breastfeeding, Undocumented Test Indication	0	
Pregnant, Undocumented Test Indication	0	
Undocumented Test Indication	0	
<15, Routine, Unknown Sex	0	
<15, Targeted, Unknown Sex	0	
<15, Undocumented Test Indication, Female	0	
<15, Undocumented Test Indication, Male	0	
<15, Undocumented Test Indication, Unknown Sex	0	
15+, Routine, Unknown Sex	0	
15+, Targeted, Unknown Sex	0	
15+, Undocumented Test Indication, Female	0	
15+, Undocumented Test Indication, Male	0	
15+, Undocumented Test Indication, Unknown Sex	0	
Unknown Age, Targeted, Female	0	
Unknown Age, Targeted, Male	0	
Pregnant, Undocumented Test Indication	27	
Undocumented Test Indication	0	
Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,617	
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	17,350	
	15+, Routine, Unknown Sex         15+, Targeted, Unknown Sex         15+, Undocumented Test Indication, Female         15+, Undocumented Test Indication, Male         15+, Undocumented Test Indication, Unknown Sex         Unknown Age, Targeted, Female         Unknown Age, Targeted, Male         Unknown Age, Undocumented Test Indication, Female         Unknown Age, Undocumented Test Indication, Male         Breastfeeding, Undocumented Test Indication         Pregnant, Undocumented Test Indication         Undocumented Test Indication         Vidocumented Test Indication, Female         <15, Routine, Unknown Sex	



	stopped ART, and those lost to follow-up		
	Numerator by Status: Pregnant	935	
TX_RET_DSD		1,033	
TX_RET_DSD			
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment6,at 12 months after initiating ART)		
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,441	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,712	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,491	



TB_PREV_DSDThe number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period34,733TB_PREV_DSDThe number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period)38,525TB_PREV_DSDBy Age/Sex (Denominator): <15, Female200TB_PREV_DSDBy Age/Sex (Denominator): <15, Female200TB_PREV_DSDBy Age/Sex (Denominator): <15, Male20,66TB_PREV_DSDBy Age/Sex (Denominator): <15, Male14,689TB_PREV_DSDBy Age/Sex (Denominator): <15, Female20,06TB_PREV_DSDBy Age/Sex (Numerator): <15, Male14,689TB_PREV_DSDBy Age/Sex (Numerator): <15, Male14,689TB_PREV_DSDBy Age/Sex (Numerator): <15, Male14,689TB_PREV_DSDBy Age/Sex (Numerator): <15, Male13,248TB_PREV_DSDBy Age/Sex (Numerator): <15, Male13,248TB_PREV_DSDBy Age/Sex (Numerator): <15, Male13,248TB_PREV_DSDBy Age/Sex (Numerator): <15, Male13,350TX_TB_DSDNumber of ART patients who were started on TB treatment during the reporting period1,350TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female16TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female16TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female16TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female <td< th=""><th></th><th></th><th></th></td<>				
TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).38,525TB_PREV_DSDBy Age/Sex (Denominator): <15, Female	TB_PREV_DSD	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting		
TB_PREV_DSDBy Age/Sex (Denominator): <15, Male206TB_PREV_DSDBy Age/Sex (Denominator): 15+, Female23,430TB_PREV_DSDBy Age/Sex (Denominator): 15+, Female23,430TB_PREV_DSDBy Age/Sex (Denominator): 15+, Male14,689TB_PREV_DSDBy Therapy type (Denominator): 6-12 Month IPT38,531TB_PREV_DSDBy Age/Sex (Numerator): 6-12 Month IPT38,531TB_PREV_DSDBy Age/Sex (Numerator): 6-12 Month IPT38,531TB_PREV_DSDBy Age/Sex (Numerator): 15-, Female194TB_PREV_DSDBy Age/Sex (Numerator): <15, Male	TB_PREV_DSD	TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period 		
TB_PREV_DSDBy Age/Sex (Denominator): 15+, Female23,430TB_PREV_DSDBy Age/Sex (Denominator): 15+, Male14,689TB_PREV_DSDBy Therapy type (Denominator): 6-12 Month IPT38,531TB_PREV_DSDBy Age/Sex (Numerator): <15, Female	TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	200	
TB_PREV_DSDBy Age/Sex (Denominator): 15+, Male14,689TB_PREV_DSDBy Therapy type (Denominator): 6-12 Month IPT38,531TB_PREV_DSDBy Age/Sex (Numerator): <15, Female	TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	206	
TB_PREV_DSDBy Therapy type (Denominator): 6-12 Month IPT38,531TB_PREV_DSDBy Age/Sex (Numerator): <15, Female	TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	23,430	
TB_PREV_DSDBy Age/Sex (Numerator): <15, Female194TB_PREV_DSDBy Age/Sex (Numerator): <15, Male	TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	14,689	
TB_PREV_DSDBy Age/Sex (Numerator): <15, Male200TB_PREV_DSDBy Age/Sex (Numerator): 15+, Female21,091TB_PREV_DSDBy Age/Sex (Numerator): 15+, Female13,248TB_PREV_DSDBy Therapy type (Numerator): 6-12 Month IPT34,733TX_TB_DSDNumber of ART patients who were started on TB treatment during the reporting period.1,350TX_TB_DSDNumber of ART patients who were screened for TB at least once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	38,531	
TB_PREV_DSDBy Age/Sex (Numerator): 15+, Female21,091TB_PREV_DSDBy Age/Sex (Numerator): 15+, Male13,248TB_PREV_DSDBy Therapy type (Numerator): 6-12 Month IPT34,733TX_TB_DSDNumber of ART patients who were started on TB treatment during the reporting period.1,350TX_TB_DSDNumber of ART patients who were screened for TB at least once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	194	
TB_PREV_DSDBy Age/Sex (Numerator): 15+, Male13,248TB_PREV_DSDBy Therapy type (Numerator): 6-12 Month IPT34,733TX_TB_DSDNumber of ART patients who were started on TB treatment during the reporting period.1,350TX_TB_DSDNumber of ART patients who were screened for TB at least once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	200	
TB_PREV_DSDBy Therapy type (Numerator): 6-12 Month IPT34,733TX_TB_DSDNumber of ART patients who were started on TB treatment during the reporting period.1,350TX_TB_DSDNumber of ART patients who were screened for TB at least once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	21,091	
TX_TB_DSDNumber of ART patients who were started on TB treatment during the reporting period.1,350TX_TB_DSDNumber of ART patients who were screened for TB at least once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	13,248	
TX_TB_DSDtreatment during the reporting period.1,350TX_TB_DSDNumber of ART patients who were screened for TB at least once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	34,733	
TX_TB_DSDleast once during the reporting period99,868TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Female	TX_TB_DSD		1,350	
TX_TB_DSDNumerator: By Aggregated Age/Sex: <15, Male17TX_TB_DSDNumerator: By Aggregated Age/Sex: 15+, Female788TX_TB_DSDNumerator: By Aggregated Age/Sex: 15+, Male529TX_TB_DSDDenominator: By Aggregated Age/Sex: <15, Female	TX_TB_DSD		99,868	
TX_TB_DSDNumerator: By Aggregated Age/Sex: 15+, Female788TX_TB_DSDNumerator: By Aggregated Age/Sex: 15+, Male529TX_TB_DSDDenominator: By Aggregated Age/Sex: <15, Female	TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	16	
TX_TB_DSDNumerator: By Aggregated Age/Sex: 15+, Male529TX_TB_DSDDenominator: By Aggregated Age/Sex: <15, Female	TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	17	
TX_TB_DSDDenominator: By Aggregated Age/Sex: <15, Female1,784TX_TB_DSDDenominator: By Aggregated Age/Sex: <15, Male	TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	788	
TX_TB_DSD       Denominator: By Aggregated Age/Sex: <15, Male       1,806         TX_TB_DSD       Denominator: By Aggregated Age/Sex:15+, Female       59,114	TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	egated Age/Sex: 15+, Male 529	
TX_TB_DSD     Denominator: By Aggregated Age/Sex:15+, Female     59,114	TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,784	
	TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,806	
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 37,164	TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	59,114	
	TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	37,164	



TX_TB_DSD	Denominator: By Screen Result: Negative 94,876	
TX_TB_DSD	Denominator: By Screen Result: Positive	4,992
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,992

### Implementing Mechanism Details

Mechanism ID: 17429	Mechanism Name: LDF Comprehensive Clinical Support Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services Int	ernational
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 270,503	Total Mechanism Pipeline: N/A
Applied Dipoline Amounts 245 024	

Total All Funding Sources: 270,503	i otal Mechanism Pipeline: N/A	
Applied Pipeline Amount: 245,034		
Total All Funding Sources and Applied Pipeline Amount: 515,537		
Funding Source	Funding Amount	
GHP-State	270,503	

# Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	35,000
Condom procurement	1,000
Condom programming	1,000



Mechanism ID:	17429		
Mechanism Name:	Mechanism Name: LDF Comprehensive Clinical Support Program		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	25,848	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	43,984	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	55	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	28,594	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	171,844	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	178	0

# Implementing Mechanism Indicator Information

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary	957



	medical male circumcision (VMMC) for HIV prevention	
	program within the reporting period	
VMMC_CIRC_DSD	By Age: 15-19	227
VMMC_CIRC_DSD	By Age: 20-24	324
VMMC_CIRC_DSD	By Age: 25-29	138
VMMC_CIRC_DSD	By Age: 30-49	172
VMMC_CIRC_DSD	By Age: 50+	96
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	647
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	957
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	957
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,920
HTC_TST_DSD	By Test Result: Positive	437
HTC_TST_DSD	Sum of Test Result disaggregates	437
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	12



Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	4
Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	20
Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	4
Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	15
Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	5
Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	14
Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	2
Service Delivery Point (Community) Mobile Testing: 15- 19, Female, Negative	77
Service Delivery Point (Community) Mobile Testing: 15- 19, Female, Positive	4
Service Delivery Point (Community) Mobile Testing: 15- 19, Male, Negative	63
Service Delivery Point (Community) Mobile Testing: 15- 19, Male, Positive	3
Service Delivery Point (Community) Mobile Testing: 20- 24, Female, Negative	194
Service Delivery Point (Community) Mobile Testing: 20- 24, Female, Positive	18
Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative	113
Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Positive	21
Service Delivery Point (Community) Mobile Testing: 25- 49, Female, Negative	173
Service Delivery Point (Community) Mobile Testing: 25- 49, Female, Positive	15
	Female, Positive         Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative         Service Delivery Point (Facility) Inpatient: 50+, Female, Negative         Service Delivery Point (Facility) Inpatient: 50+, Female, Negative         Service Delivery Point (Facility) Inpatient: 50+, Female, Positive         Service Delivery Point (Facility) Inpatient: 50+, Male, Negative         Service Delivery Point (Facility) Inpatient: 50+, Male, Negative         Service Delivery Point (Facility) Inpatient: 50+, Male, Negative         Service Delivery Point (Community) Mobile Testing: 15- 19, Female, Negative         Service Delivery Point (Community) Mobile Testing: 15- 19, Female, Positive         Service Delivery Point (Community) Mobile Testing: 15- 19, Male, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Female, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Female, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative         Service Delivery Point (Community) Mobile Testing: 20- 24, Male, Negative         Service Delivery Point (Community) Mobile Testing: 25- 49, Female,



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25- 49, Male, Negative	82
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25- 49, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	254
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	265
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	38



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	13



		1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	259
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	95



HTC_TST_DSDService Delivery Point (Facility) VCT: 25-49, Female, Positive19HTC_TST_DSDService Delivery Point (Facility) VCT: 25-49, Male, Negative85HTC_TST_DSDService Delivery Point (Facility) VCT: 25-49, Male, Positive13HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Negative100HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Positive14HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive16TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)140TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases, during the reporting period)140Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapse			
HTC_ISI_DSDNegative85HTC_TST_DSDService Delivery Point (Facility) VCT: 25-49, Male, Positive13HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Negative100HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Positive14HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive16TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Semale 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting	HTC_TST_DSD		19
HTC_TST_DSDPositive13HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Negative100HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Positive14HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive16TB_STAT_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive200TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)76TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and re	HTC_TST_DSD		85
HIC_TSI_DSDNegative100HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Female, Positive14HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive16TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDTotal number of registered new and relapsed TB cases with documented HIV status, during the reporting period.140TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases, during the reporting period)75	HTC_TST_DSD		13
HTC_TST_DSD14HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Negative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive16TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)140TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases, during the reporting period)76 </td <td>HTC_TST_DSD</td> <td></td> <td>100</td>	HTC_TST_DSD		100
HTC_TST_DSDNegative89HTC_TST_DSDService Delivery Point (Facility) VCT: 50+, Male, Positive16TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)140TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDAggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases with documented HIV-positive status who are on ART during TB treatment during the reporti	HTC_TST_DSD		14
HIC_ISI_DSDPositive16TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.200TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.250TB_STAT_DSDAggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)140TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period108	HTC_TST_DSD		89
TB_STAT_DSD       documented HIV status, during the reporting period.       200         TB_STAT_DSD       Total number of registered new and relapsed TB cases, during the reporting period.       250         TB_STAT_DSD       Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       140         TB_STAT_DSD       Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       60         TB_STAT_DSD       Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)       60         TB_STAT_DSD       Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)       175         TB_STAT_DSD       Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)       175         TB_STAT_DSD       Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)       175         TB_STAT_DSD       Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)       108         TB_ART_DSD       The number of registered new and relapse TB cases       75         TB_ART_DSD       The number of registered new and relapse TB cases	HTC_TST_DSD		16
TB_STAT_DSDduring the reporting period.250Magregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with140TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number documented HIV status, during the reporting period)140TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_STAT_DSDThe number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period108	TB_STAT_DSD		200
TB_STAT_DSDregistered new and relapsed TB cases with documented HIV status, during the reporting period)140TB_STAT_DSDAggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapsed TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period108	TB_STAT_DSD		250
TB_STAT_DSDof registered new and relapsed TB cases with documented HIV status, during the reporting period)60TB_STAT_DSDAggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period108	TB_STAT_DSD	registered new and relapsed TB cases with	140
TB_STAT_DSDnumber of registered new and relapsed TB cases, during the reporting period)175TB_STAT_DSDAggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)75TB_ART_DSDThe number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period108	TB_STAT_DSD	of registered new and relapsed TB cases with	60
TB_STAT_DSD       number of registered new and relapsed TB cases, during the reporting period)       75         TB_ART_DSD       The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period       108	TB_STAT_DSD	number of registered new and relapsed TB cases,	175
TB_ART_DSD       with documented HIV-positive status who are on ART       108         during TB treatment during the reporting period       108	TB_STAT_DSD	number of registered new and relapsed TB cases,	75
TB_ART_DSD The number of registered new and relapse TB cases 108	TB_ART_DSD	with documented HIV-positive status who are on ART	108
	TB_ART_DSD	The number of registered new and relapse TB cases	108



	- <u> </u>	
	with documented HIV-positive status during TB	
	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	32
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	32
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,266
TX_CURR_DSD	Age/Sex: 15-19 Male	3
TX_CURR_DSD	Age/Sex: 15-19 Female	5
TX_CURR_DSD	Sum of age/sex disaggregates	8
TX_CURR_DSD	Age/Sex: 20-24 Male	514
TX_CURR_DSD	Age/Sex: 25-49 Male	834
TX_CURR_DSD	Age/Sex: 50+ Male	230
TX_CURR_DSD	Age/Sex: 20-24 Female	225
TX_CURR_DSD	Age/Sex: 25-49 Female	356
TX_CURR_DSD	Age/Sex: 50+ Female	96
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	342
TX_NEW_DSD	By Age/Sex: 15-19 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	35
TX_NEW_DSD	By Age/Sex: 25-49 Male	115



TX_NEW_DSD	By Age/Sex: 50+ Male	79
TX_NEW_DSD	By Age/Sex: 15-19 Female	17
TX_NEW_DSD	By Age/Sex: 20-24 Female	31
TX_NEW_DSD	By Age/Sex: 25-49 Female	50
TX_NEW_DSD	By Age/Sex: 50+ Female	11
TX_NEW_DSD	Sum of Age/Sex disaggregates	343
TX_NEW_DSD	Pregnancy status	5
TX_NEW_DSD	Breastfeeding status	2
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,935
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,037
TX_PVLS_DSD	Numerator: Indication: Routine	1,931
TX_PVLS_DSD	Numerator: Indication: Targeted	4
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	39
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	10
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,347
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	584
TX_PVLS_DSD	Denominator: Indication: Routine	2,033
TX_PVLS_DSD	Denominator: Indication: Targeted	4
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	41
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	11



	<u> </u>	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,418
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	615
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	431
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	500
TX_RET_DSD	Numerator by Status: Pregnant	37
TX_RET_DSD	Numerator by Status: Breastfeeding	10
TX_RET_DSD	Denominator by Status: Pregnant	41
TX_RET_DSD	Denominator by Status: Breastfeeding	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	297
TX_RET_DSD	_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	349
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	151



TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	219
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	274
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	86
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	188
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	246
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	28
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	74
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	145
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	175
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	44
TX_TB_DSD	Number of ART patients who were started on TB           treatment during the reporting period.	
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,038
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	11
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	21
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	644
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,394
TX_TB_DSD	Denominator: By Screen Result: Negative	1,834
TX_TB_DSD	Denominator: By Screen Result: Positive	204
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	194
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	184



TX_TB_DSD       Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	10
---	----

#### Implementing Mechanism Details

Mechanism ID: 17431	Mechanism Name: Support Laboratory Diagnosis and Monitoring to Scale up and Improve HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: University Research Corporati	on, LLC		
Agreement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No Managing Agency:			

Total All Funding Sources: 1,310,000	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 1,310,000				
Funding Source Funding Amount				
GHP-State	1,310,000			

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

## **Budget Code Information**

Mechanism ID	17431
Mechanism Name	Support Laboratory Diagnosis and Monitoring to Scale up and Improve
Prime Partner Name	HIV/AIDS Care and Treatment Services in the Kingdom of Lesotho under
	the President's Emergency Plan for AIDS Relief (PEPFAR)



	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	460,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

#### Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 17432	Mechanism Name: Support Ministry of Health to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health (MOH)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 6,199,199	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 6,199,199	
Funding Source Funding Amount		
GHP-State	6,199,199	

Human Resources for Health	200,000

## Budget Code Information

Mechanism Name:	<ul> <li>17432</li> <li>Support Ministry of Health to Strengthen Health Systems and Coordinate</li> <li>HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of</li> <li>Lesotho under the President's Emergency Plan for AIDS Relief (PEPFAR)</li> <li>Ministry of Health (MOH)</li> </ul>		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	507,553	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	499,848	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	355,950	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HLAB	200,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,360,960	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	194,888	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR- supported strengthening efforts, within the reporting period, by select cadre	1
HRH_PRE	By Graduates: Other	1
HRH_PRE	Sum of Graduates disaggreagtes	1

#### Implementing Mechanism Details

Mechanism ID: 17549	Mechanism Name: TSEPO
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 3,312,197	Total Mechanism Pipeline: N/A

Applied Pipeline Amount: 0



Total All Funding Sources and Applied Pipeline Amount: 3,312,197	
Funding Source	Funding Amount
GHP-State	3,312,197

Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Motor Vehicles: Purchased	90,976
Human Resources for Health	100,000

#### **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:	TSEPO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	109,873	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	389,849	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,812,475	0

#### Implementing Mechanism Indicator Information



Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	49,226
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	11,478
VMMC_CIRC_DSD	By Age: 15-19	13,213
VMMC_CIRC_DSD	By Age: 20-24	13,210
VMMC_CIRC_DSD	By Age: 25-29	11,325
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	37,901
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	49,226
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	49,226
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	15,466
PrEP_NEW_DSD	Male 15-19	143
PrEP_NEW_DSD	Male 20-24	143
PrEP_NEW_DSD	Male 25-49	475
PrEP_NEW_DSD	Male 50+	190
PrEP_NEW_DSD	Female 15-19	2,177
PrEP_NEW_DSD	Female 20-24	2,177
PrEP_NEW_DSD	Female 25-49	7,258
PrEP_NEW_DSD	Female 50+	2,903
PrEP_NEW_DSD	FSW	570
PrEP_NEW_DSD	MSM	951
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,198
HTC_TST_DSD	By Test Result: Positive	1,024

Page 156 of 191

FACTS Info v3.8.21.10



HTC_TST_DSD	Sum of Test Result disaggregates	1,024
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	12,102
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	184
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,911
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	2,165
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	715
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0

## Implementing Mechanism Details

Mechanism ID: 18020	Mechanism Name: Providing Universal Services for HIV/AIDS (PUSH)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 12,945,811	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,742,602		
Total All Funding Sources and Applied Pipeline Amount: 14,688,413		
Funding Source	Funding Amount	
GHP-State	12,945,811	

Sub Area: Gender: Gender Equality	15,000 GBV Prevention Implementation Capacity building 30,000
Sub Area: Sub Area: Gender: Gender Equality	Implementation Capacity building 30,000
Sub Area: Gender: Gender Equality	Capacity building 30,000
Gender: Gender Equality	30,000
· · _ · _ ·	
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Water	200,000



Human Resources for Health	1,000,000
----------------------------	-----------

Mechanism ID:	18020		
	-	vices for HIV/AIDS (PUSH	)
Prime Partner Name:	Elizabeth Glaser Pediatr	ic AIDS Foundation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,487,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,662,824	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	178,197	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,400,126	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,068,127	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	267,499	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,278,203	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	603,085	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,009
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,202
PMTCT_ART_DSD	New on ART	3,618
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,391
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,202
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,755
PMTCT_STAT_DSD	By Age (Denominator): 20-24	10,018
PMTCT_STAT_DSD	By Age (Denominator): 25-49	13,005
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	980
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,717
PMTCT_STAT_DSD	By Number of known positives: 25-49	2,206
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	487
PMTCT_STAT_DSD	By Number of new positives: 20-24	859



PMTCT_STAT_DSD	By Number of new positives: 25-49	1,089
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,174
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,380
PMTCT_STAT_DSD	By Number of new negative: 25-49	9,310
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	5,645
PMTCT_STAT_DSD	By Age (Numerator): 20-24	9,834
PMTCT_STAT_DSD	By Age (Numerator): 25-49	12,723
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,786
PrEP_NEW_DSD	Male 15-19	300
PrEP_NEW_DSD	Male 20-24	296
PrEP_NEW_DSD	Male 25-49	985
PrEP_NEW_DSD	Male 50+	445
PrEP_NEW_DSD	Female 15-19	254
PrEP_NEW_DSD	Female 20-24	264
PrEP_NEW_DSD	Female 25-49	882
PrEP_NEW_DSD	Female 50+	360
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	383,728
HTC_TST_DSD	By Test Result: Positive	34,507
HTC_TST_DSD	Sum of Test Result disaggregates	34,507



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	339
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	644
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	282
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	4,072
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	407
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	2,723
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	269
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,038
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female,	105



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	658
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,067
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	10,450
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	11,934
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,563
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	464
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,996
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	272
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	12,523
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,375
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,225
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	713
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49,	73,274



Female, NegativeHTC_TST_DSDService Delivery Point (Facility) Other PITC: 25-49, Male, Negative10,321HTC_TST_DSDService Delivery Point (Facility) Other PITC: 25-49, Male, Negative49,530HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative6,805HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative18,963HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative2,743HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Positive12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Negative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Negative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Negative14,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Negative29HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Negative29HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative6,809HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative226HTC_TST_DSDService Delivery Point (Facility) TB: 10-14, Female, Negative256HTC_TST_DSDService Delivery Point (Facility) TB: 10-14, Female, Negative21HTC_TST_DSDService Delivery Point (Facility) TB: 10-14, Male, Negative313HTC_TST_DSD			
HIC_TST_DSDFemale, Positive10,321HTC_TST_DSDService Delivery Point (Facility) Other PITC: 25-49, Male, Negative49,530HTC_TST_DSDService Delivery Point (Facility) Other PITC: 25-49, Male, Positive6,805HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative18,963HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Positive2,743HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive37,283HTC_TST_DSDService Delivery Point (Facility) Pother PITC: <1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative		Female, Negative	
HTC_TST_DSDMale, Negative49,530HTC_TST_DSDService Delivery Point (Facility) Other PITC: 25-49, Male, Positive6,805HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative18,963HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative2,743HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Positive12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Positive1,710HTC_TST_DSDService Delivery Point (Facility) Other PITC: 41, Positive4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: 41, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		10,321
HTC_TST_DSDMale, Positive6,805HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Negative18,963HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Positive2,743HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Negative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Negative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Negative1,710HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Negative4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		49,530
HTC_TST_DSDFemale, Negative18,963HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Female, Positive2,743HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Negative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility)Other PITC: <1, Negative4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		6,805
HTC_ISI_DSDFemale, Positive2,743HTC_ISI_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Negative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility)Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility)Other PITC: <1, Negative4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		18,963
HTC_TST_DSDNegative12,319HTC_TST_DSDService Delivery Point (Facility) Other PITC: 50+, Male, Positive1,710HTC_TST_DSDService Delivery Point (Facility)Other PITC: <1, Negative4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		2,743
HTC_TST_DSDPositive1,710HTC_TST_DSDService Delivery Point (Facility)Other PITC: <1, Negative4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		12,319
HTC_TST_DSDNegative4,147HTC_TST_DSDService Delivery Point (Facility) Other PITC: <1, Positive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		1,710
HTC_TST_DSDPositive29HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Negative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		4,147
HTC_TST_DSDNegative37,283HTC_TST_DSDService Delivery Point (Facility) Other PITC: 1-9, Positive383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		29
HTC_TST_DSD383HTC_TST_DSDService Delivery Point (Facility) Pediatric : <5 Negative	HTC_TST_DSD		37,283
HTC_TST_DSD       Service Delivery Point (Facility) Pediatric : <5 Positive	HTC_TST_DSD		383
HTC_TST_DSD       Service Delivery Point (Facility) TB: 10-14, Female, Negative       256         HTC_TST_DSD       Service Delivery Point (Facility) TB: 10-14, Female, Positive       2         HTC_TST_DSD       Service Delivery Point (Facility) TB: 10-14, Male, Negative       313         HTC_TST_DSD       Service Delivery Point (Facility) TB: 10-14, Male, Negative       313	HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	6,809
HTC_TST_DSD     256       HTC_TST_DSD     Service Delivery Point (Facility) TB: 10-14, Female, Positive     2       HTC_TST_DSD     Service Delivery Point (Facility) TB: 10-14, Male, Negative     313       HTC_TST_DSD     Service Delivery Point (Facility) TB: 10-14, Male, Service Delivery Point (Facility) TB: 10-14, Male,     313	HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	226
HTC_TST_DSD     2       HTC_TST_DSD     Service Delivery Point (Facility) TB: 10-14, Male, Negative     313       HTC_TST_DSD     Service Delivery Point (Facility) TB: 10-14, Male, Service Delivery Point (Facility) TB: 10-14, Male,     2	HTC_TST_DSD		256
HTC_TST_DSD     313       HTC_TST_DSD     Service Delivery Point (Facility) TB: 10-14, Male,     2	HTC_TST_DSD		2
I HTC TST DSD   2	HTC_TST_DSD		313
	HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	2
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, 172	HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	172



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	607
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	3,529
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	603
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	2,355
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	400
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	915
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	157
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	597
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	962
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	9

Page 165 of 191

FACTS Info v3.8.21.10



HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2,533
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	2,909
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	987
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	547
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,596
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	291
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,402
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	19,957
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	2,263
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	13,408
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,481
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	5,232



HTC_TST_DSD         Service Delivery Point (Facility) Index: 50+, Female, Positive         617           HTC_TST_DSD         Service Delivery Point (Facility) Index: 50+, Male, Negative         3,480           HTC_TST_DSD         Service Delivery Point (Facility) Index: 50+, Male, Positive         374           HTC_TST_DSD         Service Delivery Point (Facility) Index: <1, Negative         999           HTC_TST_DSD         Service Delivery Point (Facility) Index: <1, Positive         3           HTC_TST_DSD         Service Delivery Point (Facility) Index: <1, Positive         3           HTC_TST_DSD         Service Delivery Point (Facility) Index: <1, Positive         9,081           HTC_TST_DSD         Service Delivery Point (Facility) ANC: <1, Positive         0           HTC_TST_DSD         Service Delivery Point (Facility) ANC: <1, Negative         0           HTC_TST_DSD         Service Delivery Point (Facility) ANC: <1, Positive         0           HTC_TST_DSD         Service Delivery Point (Facility) ANC: <1, Positive         0           HTC_TST_DSD         Service Delivery Point (Facility) ANC: <1, Positive         0           HTC_TST_DSD         Service Delivery Point (Facility) ANC: <1, Positive         0           HTC_TST_DSD         Service Delivery Point (Facility) ANC: 10-14, Negative         0           HTC_TST_DSD         Service Delivery Point (Facility) AN			
HTC_TST_DSDNegative3,480HTC_TST_DSDService Delivery Point (Facility) Index: 50+, Male, Positive374HTC_TST_DSDService Delivery Point (Facility) Index: <1, Negative	HTC_TST_DSD		617
HTC_TST_DSDPositive374HTC_TST_DSDService Delivery Point (Facility) Index: <1, Negative	HTC_TST_DSD		3,480
HTC_TST_DSDService Delivery Point (Facility) Index: <1, Positive3HTC_TST_DSDService Delivery Point (Facility) Index: 1-9, Negative9,081HTC_TST_DSDService Delivery Point (Facility) Index: 1-9, Positive81HTC_TST_DSDService Delivery Point (Facility) ANC: <1, Negative	HTC_TST_DSD		374
HTC_TST_DSDService Delivery Point (Facility) Index: 1-9, Negative9,081HTC_TST_DSDService Delivery Point (Facility) Index: 1-9, Positive81HTC_TST_DSDService Delivery Point (Facility) ANC: <1, Negative	HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	999
HTC_TST_DSDService Delivery Point (Facility) Index: 1-9, Positive81HTC_TST_DSDService Delivery Point (Facility) ANC: <1, Negative	HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSDService Delivery Point (Facility) ANC: <1, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: <1, Positive	HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	9,081
HTC_TST_DSDService Delivery Point (Facility) ANC: <1, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 10-14, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 10-14, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 10-14, Negative1,646HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Negative1,646HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Negative143HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative378HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative0Ntrc_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknow	HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	81
HTC_TST_DSDService Delivery Point (Facility) ANC: 10-14, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 10-14, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Negative1,646HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Negative143HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative378HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative0Service Delivery Point (Facility) ANC: 50+, Positive00HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Ag	HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSDService Delivery Point (Facility) ANC: 10-14, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Negative1,646HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Positive143HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative378HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery	HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Negative1,646HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Positive143HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility)	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_DSDService Delivery Point (Facility) ANC: 15-19, Positive143HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative378HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative789HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0TB_STAT_DSDNumber of registered	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative378HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 10known Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive10,153 <td>HTC_TST_DSD</td> <td>Service Delivery Point (Facility) ANC: 15-19, Negative</td> <td>1,646</td>	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,646
HTC_TST_DSDService Delivery Point (Facility) ANC: 1-9, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Positive789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive10	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	143
HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Negative4,357HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Positive789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTG_TST_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSDService Delivery Point (Facility) ANC: 20-24, Positive378HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDTotal number of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Negative9,006HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Positive789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	4,357
HTC_TST_DSDService Delivery Point (Facility) ANC: 25-49, Positive789HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: 0+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	378
HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Negative54HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	9,006
HTC_TST_DSDService Delivery Point (Facility) ANC: 50+, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	789
HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Negative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	54
HTC_TST_DSDNegative0HTC_TST_DSDService Delivery Point (Facility) ANC: Unknown Age, Positive0TB_STAT_DSDNumber of registered new and relapsed TB cases with documented HIV status, during the reporting period.10,153TB_STAT_DSDTotal number of registered new and relapsed TB cases, during the reporting period.10,153	HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD     O       Positive     0       TB_STAT_DSD     Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.     10,153       TB_STAT_DSD     Total number of registered new and relapsed TB cases, during the reporting period.     10,153	HTC_TST_DSD		0
TB_STAT_DSD     10,153       documented HIV status, during the reporting period.     10,153       TB_STAT_DSD     Total number of registered new and relapsed TB cases, during the reporting period.     10,153	HTC_TST_DSD		0
TB_STAT_DSD during the reporting period. 10,153	TB_STAT_DSD		10,153
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of 174	TB_STAT_DSD		10,153
	TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	174



	registered new and relapsed TB cases with	
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	6,108
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	126
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	3,745
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	174
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	6,110
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	126
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	3,743
	during the reporting period)	
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status who are on ART	7,231
	during TB treatment during the reporting period	
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status during TB	7,231
	treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The	
	number of registered new and relapse TB cases with	
TB_ART_DSD	documented HIV-positive status who are on ART during	121
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The	
TB_ART_DSD	number of registered new and relapse TB cases with	4,353



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	91
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,666
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	121
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,353
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	91
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2,666
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,976
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	46
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	5,542
PMTCT_EID_DSD	Number of infants with a positive virological test result	44



	between 2 and 12 months of birth	
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,344
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	154,565
TX_CURR_DSD	Age/Sex: 15-19 Male	1,646
TX_CURR_DSD	Age/Sex: 15-19 Female	2,801
TX_CURR_DSD	Sum of age/sex disaggregates	4,447
TX_CURR_DSD	Age/Sex: <1	406
TX_CURR_DSD	Age/Sex: <1-9	3,662
TX_CURR_DSD	Age/Sex: 10-14 Male	1,076
TX_CURR_DSD	Age/Sex: 10-14 Female	1,083
TX_CURR_DSD	Age/Sex: 20-24 Male	4,352
TX_CURR_DSD	Age/Sex: 25-49 Male	41,551
TX_CURR_DSD	Age/Sex: 50+ Male	10,084
TX_CURR_DSD	Age/Sex: 20-24 Female	8,330
TX_CURR_DSD	Age/Sex: 25-49 Female	63,129
TX_CURR_DSD	Age/Sex: 50+ Female	16,445
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	47,554
TX_NEW_DSD	By Age/Sex: <1	55
TX_NEW_DSD	By Age/Sex: 1-9	551
TX_NEW_DSD	By Age/Sex: 10-14 Male	167
TX_NEW_DSD	By Age/Sex: 15-19 Male	511
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,360
TX_NEW_DSD	By Age/Sex: 25-49 Male	13,085
TX_NEW_DSD	By Age/Sex: 50+ Male	3,155
TX_NEW_DSD	By Age/Sex: 10-14 Female	164
TX_NEW_DSD	By Age/Sex: 15-19 Female	878
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,621
TX_NEW_DSD	By Age/Sex: 25-49 Female	19,852
TX_NEW_DSD	By Age/Sex: 50+ Female	5,155



TX_NEW_DSD	Sum of Age/Sex disaggregates	46,948
	Sum of Age/Sex disaggregates	
TX_NEW_DSD	Pregnancy status	3,614
TX_NEW_DSD	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	120,940
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	134,300
TX_PVLS_DSD	Numerator: Indication: Routine	120,940
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	11,543
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,334
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	45,348
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,344
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	70,918
TX_PVLS_DSD	Denominator: Indication: Routine	134,300
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	12,804
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,562
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	50,380
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,573
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	78,785
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0



TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	30,548
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	33,848
TX_RET_DSD	Numerator by Status: Pregnant	1,707
TX_RET_DSD	Denominator by Status: Pregnant	1,887
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	309
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,676
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	302
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18,259
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	315
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	12,946



	12 months prior to the beginning of the reporting period,	
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	307
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_DSD	12 months prior to the beginning of the reporting period,	20,280
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	The number of ART patients who completed a course	
TB_PREV_DSD	of TB preventive therapy or at least 6 months of	38,730
	Isoniazid Preventive Therapy (IPT) during the reporting	
	period	
	The number of ART patients who were newly started on	
	TB preventive therapy (including those who newly	
TB_PREV_DSD	started on TB preventive therapy in this reporting period and those who started in the previous reporting period	42,879
	but had not been reported as they did not fulfill the	42,075
	minimum requirements for the previous reporting	
	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	462
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	470
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	25,549
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	16,398
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	42,879
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	454
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	463
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	23,004
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	14,809
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	38,730



TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	2,039
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	142,670
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	33
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	32
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1,203
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	771
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,087
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,077
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	83,490
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	53,016
TX_TB_DSD	Denominator: By Screen Result: Negative	135,534
TX_TB_DSD	Denominator: By Screen Result: Positive	7,136
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	7,136
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	7,136

#### **Implementing Mechanism Details**

Mechanism ID: 18048	Mechanism Name: Global Health Supply Chain Management
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Health Supply Chain Pr	ogram
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 2,000,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	e Amount: 2,000,000
Funding Source	Funding Amount
GHP-USAID	2,000,000

Human Resources for Health 250,000
------------------------------------

#### **Budget Code Information**

Mechanism ID:	18048		
Mechanism Name:	Mechanism Name: Global Health Supply Chain Management		
Prime Partner Name:	Global Health Supply Ch	nain Program	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	200,000	0



#### Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 18143	Mechanism Name: 4Children – Coordinating Comprehensive Care for Children	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Catholic Relief Services		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 2,040,131	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 2,040,131	
Funding Source		

Funding Source	Funding Amount
GHP-State	2,040,131

#### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting
	positive gender norms
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that
	increase legal protection



Mechanism ID:	18143		
Mechanism Name:	4Children – Coordinating Comprehensive Care for Children		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,040,131	0

#### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	38,667
OVC_SERV_DSD	By: Age/sex: Male 25+	545
OVC_SERV_DSD	Age/Sex: 10-14 Female	6,870
OVC_SERV_DSD	Age/Sex: 15-17 Female	16,666
OVC_SERV_DSD	By: Age/sex: 18-24 Female	6,746
OVC_SERV_DSD	By: Age/sex: 25+ Female	5,840
OVC_SERV_DSD	Sum of Age/Sex disaggregates	23,536
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,240
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	2,710
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	450
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	3,330
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	270
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	4,600
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	9,686



	and sex: Social Protection Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	4,581
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	980
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	4,070
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,735
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	2,440
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	275
OVC_SERV_DSD	Age/Sex: <1	2,000
OVC_SERV_DSD	Program Completion: Active	38,667

#### **Implementing Mechanism Details**

Mechanism ID: 18227	TBD: Yes
REDACTED	

#### **Implementing Mechanism Details**

Mechanism ID: 18235	Mechanism Name: EQUIP	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Right To Care, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,250,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 1,250,000	
Funding Source	Funding Amount
GHP-USAID	1,250,000

Key Populations: MSM and TG	200,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: Gender Equality	30,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Sub Area:	Implementation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building

## Budget Code Information

Mechanism ID: 18235 Mechanism Name: EQUIP



Prime Partner Name:	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

#### Implementing Mechanism Indicator Information

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 18240	Mechanism Name: Vodafone	
Funding Agency: USAID	Procurement Type: Grant	
Prime Partner Name: Vodafone Foundation	n	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	A	
G2G: No	Managing Agency:	
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied I	Pipeline Amount: 0	

Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-USAID	0

#### Cross-Cutting Budget Attribution(s)



Mechanism ID: Mechanism Name:			
Prime Partner Name:	Vodafone Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

#### Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 18524	Mechanism Name: ICAP Global Technical Assistance
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source Funding Amount	
GHP-State	0

## Cross-Cutting Budget Attribution(s)



Mechanism ID:	18524		
Mechanism Name:	ICAP Global Technical Assistance		
Prime Partner Name:	Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

#### Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 18525	Mechanism Name: Technical Support Project (TSP) Regional Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Med	licine Children's Foundation
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,000,000       Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,000,000		
Funding Source	Funding Amount	
GHP-State	1,000,000	

## Cross-Cutting Budget Attribution(s)



Mechanism ID:	18525		
Mechanism Name:	<b>Technical Support Proje</b>	ect (TSP) Regional Progra	ım
Prime Partner Name:	<b>Baylor College of Medic</b>	ine Children's Foundatio	n
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,000,000	0

#### Implementing Mechanism Indicator Information

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 18641	TBD: Yes	
REDACTED		

#### **Implementing Mechanism Details**

Mechanism ID: 18642	TBD: Yes
REDACTED	

#### Implementing Mechanism Details

Mechanism ID: 18643	Mechanism Name: AIDSFREE					
Funding Agency: USAID	Procurement Type: Cooperative Agreement					
Prime Partner Name: John Snow Inc (JSI)						
Agreement Start Date: Redacted	Agreement End Date: Redacted					
TBD: No	New Mechanism: Yes					
Global Fund / Multilateral Engagement: N/A						
G2G: No	Managing Agency:					



Total All Funding Sources: 500,000	Total Mechanism Pipeline: N/A					
Applied Pipeline Amount: 0						
Total All Funding Sources and Applied Pipeline Amount: 500,000						
Funding Source	Funding Amount					
GHP-State	190,763					
GHP-USAID	309,237					

Gender: Gender Equality	30,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Water	50,000

#### **Budget Code Information**

Mechanism ID:	18643		
Mechanism Name:	AIDSFREE		
Prime Partner Name:	John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	500,000	0

## Implementing Mechanism Indicator Information



## Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT			128,670	128,670	0	128,670
Services			400.005	400.005	004 700	707.004
			402,265	402,265	394,736	797,001
Institutional Contractors			30,000	30,000	0	30,000
Management Meetings/Profes sional Development			177,888	177,888	0	177,888
Non-ICASS Administrative Costs			0	0	1,143,230	1,143,230
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel			200,988	200,988	0	200,988
USG Staff Salaries and Benefits - Internationally Recruited		0	1,689,935	1,689,935	0	1,689,935
USG Staff Salaries and Benefits -			211,017	211,017	0	211,017



Locally						
Recruited						
Total	0	0	2,840,763	2,840,763	1,537,966	4,378,729

## U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		2,000		2,000	0	2,000
ICASS		14,252		14,252	16,881	31,133
Institutional Contractors				0	0	0
Management Meetings/Profes sional Development		3,119		3,119	3,685	6,804
Non-ICASS Administrative Costs		2,408		2,408	945	3,353
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		6,082		6,082	7,205	13,287
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff		22,163		22,163	26,250	48,413



Approved

Recruited <b>Total</b>	0	50,024	0	50,024	54,966	104,990
Locally						
Salaries and Benefits -						
Salaries and						

# U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing	0			0	162,229	162,229
Computers/IT Services		0		0	43,000	43,000
ICASS	0	0		0	477,127	477,127
Institutional Contractors				0	0	0
Management Meetings/Profes sional Development		0		0	46,182	46,182
Non-ICASS Administrative Costs		0		0	32,143	32,143
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		192,984		192,984	0	192,984
USG Staff	512,500	971,774		1,484,274	0	1,484,274



Total	512,500	1,338,906	0	1,851,406	760,681	2,612,087
Recruited						
Locally						
Benefits -		174,148		174,148	0	174,148
Salaries and						
USG Staff						
Recruited						
Internationally						
Benefits -						
Salaries and						

## U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		4,000		4,000	0	4,000
ICASS		89,047		89,047	0	89,047
Institutional Contractors				0	0	0
Non-ICASS Administrative Costs		99,100		99,100	0	99,100
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		30,000		30,000	0	30,000
USG Staff Salaries and Benefits -		0		0	0	0



Total	0	306,717	0	306,717	0	306,717
Recruited						
Locally						
Benefits -		84,570		84,570	0	84,570
USG Staff Salaries and						
Recruited						
Internationally						

# U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Institutional Contractors				0	0	0
Non-ICASS Administrative Costs		0		0	56,436	56,436
Peace Corps Volunteer Costs		217,478		217,478	222,725	440,203
Staff Program Travel		21,132		21,132	0	21,132
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits -		62,229		62,229	0	62,229



Locally						
Recruited						
Total	0	300,839	0	300,839	279,161	580,000